WO2012169798A2 - Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same - Google Patents

Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same Download PDF

Info

Publication number
WO2012169798A2
WO2012169798A2 PCT/KR2012/004494 KR2012004494W WO2012169798A2 WO 2012169798 A2 WO2012169798 A2 WO 2012169798A2 KR 2012004494 W KR2012004494 W KR 2012004494W WO 2012169798 A2 WO2012169798 A2 WO 2012169798A2
Authority
WO
WIPO (PCT)
Prior art keywords
deleted
seq
peptide
obesity
alanine
Prior art date
Application number
PCT/KR2012/004494
Other languages
French (fr)
Other versions
WO2012169798A3 (en
Inventor
Sung Youb Jung
Myung Hyun Jang
Ling Ai Shen
Young Kyung Park
Young Jin Park
Se Chang Kwon
Original Assignee
Hanmi Science Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47296599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2012169798(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to LTEP12797363.4T priority Critical patent/LT2718318T/en
Priority to EP18177993.5A priority patent/EP3434687B1/en
Priority to CN201280038851.4A priority patent/CN103732618B/en
Priority to SG2013089065A priority patent/SG195258A1/en
Priority to MX2013014468A priority patent/MX350708B/en
Priority to EP12797363.4A priority patent/EP2718318B1/en
Priority to BR122020011001-5A priority patent/BR122020011001B1/en
Priority to CA2838503A priority patent/CA2838503C/en
Priority to PL12797363T priority patent/PL2718318T3/en
Priority to NZ618810A priority patent/NZ618810B2/en
Priority to PE2023001927A priority patent/PE20240686A1/en
Priority to JP2014514799A priority patent/JP6014127B2/en
Priority to DK12797363.4T priority patent/DK2718318T3/en
Priority to AU2012267398A priority patent/AU2012267398B2/en
Priority to EP21161174.4A priority patent/EP3878859B1/en
Priority to RU2013154066A priority patent/RU2612906C2/en
Priority to US14/124,969 priority patent/US9527898B2/en
Application filed by Hanmi Science Co., Ltd. filed Critical Hanmi Science Co., Ltd.
Priority to ES12797363.4T priority patent/ES2692187T3/en
Priority to RS20181080A priority patent/RS57711B1/en
Priority to UAA201314212A priority patent/UA114710C2/en
Priority to BR112013031794-9A priority patent/BR112013031794B1/en
Priority to SI201231406T priority patent/SI2718318T1/en
Publication of WO2012169798A2 publication Critical patent/WO2012169798A2/en
Publication of WO2012169798A3 publication Critical patent/WO2012169798A3/en
Priority to ZA2013/09054A priority patent/ZA201309054B/en
Priority to US14/748,389 priority patent/US9522946B2/en
Priority to IL245557A priority patent/IL245557B/en
Priority to US15/286,708 priority patent/US9765131B2/en
Priority to AU2016273908A priority patent/AU2016273908B2/en
Priority to US15/675,274 priority patent/US10442848B2/en
Priority to IL260582A priority patent/IL260582B/en
Priority to AU2018213964A priority patent/AU2018213964B2/en
Priority to HRP20181591TT priority patent/HRP20181591T1/en
Priority to CY181101088T priority patent/CY1120781T1/en
Priority to IL268984A priority patent/IL268984B/en
Priority to AU2020201322A priority patent/AU2020201322B2/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a novel peptide showing excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor greater than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient.
  • Obesity is a severe condition that causes various diseases worldwide. It is thought to be overcome by individual efforts, and it is also believed that obese patients lack self-control. However, it is difficult to treat obesity, because obesity is a complex disorder involving appetite regulation and energy metabolism. For the treatment of obesity, abnormal actions associated with appetite regulation and energy metabolism should be treated together with efforts of obese patients. Many attempts have been made to develop drugs capable of treating the abnormal actions. As the result of these efforts, drugs such as Rimonabant (Sanofi-Aventis), Sibutramin (Abbott), Contrave (Takeda), and Orlistat (Roche) have been developed, but they have the disadvantages of serious adverse effects or very weak anti-obesity effects.
  • glucagon derivatives have received much attention.
  • Glucagon is produced by the pancreas when the level of glucose in the blood drops resulting from other medications or diseases, hormone or enzyme deficiencies.
  • Glucagon stimulates glycogen breakdown in the liver, and facilitates glucose release to raise blood glucose levels to a normal range.
  • glucagon suppresses appetite and activates hormone-sensitive lipase(HSL) of adipocytes to facilitate lipolysis, thereby showing anti-obesity effects.
  • HSL hormone-sensitive lipase
  • GLP-1 glucagon like peptide-1
  • Exendin-4 is isolated from lizard venom that shares approximately 50% amino acid homology with GLP-1 and is also reported to activate the GLP-1 receptor, thereby ameliorating hyperglycemia in patients with diabetes.
  • anti-obesity drugs including GLP-1 are reported to show side-effects such as vomiting and nausea.
  • Oxyntomodulin a peptide derived from a glucagon precursor, pre-glucagon that binds to the receptors of two peptides, GLP-1 and glucagon.
  • Oxyntomodulin represents a potent anti-obesity therapy, because it inhibits food intake like GLP-1, promotes satiety, and has a lipolytic activity like glucagon.
  • Korean Patent No. 925017 discloses a pharmaceutical composition including oxyntomodulin as an active ingredient for the treatment of overweight human, which is administered via an oral, parenteral, mucosal, rectal, subcutaneous, or transdermal route.
  • this anti-obesity drug including oxyntomodulin has a short in vivo half-life and weak therapeutic efficacy, even though administered at a high dose three times a day.
  • many efforts have been made to improve the in vivo half-life or therapeutic effect of oxyntomodulin on obesity by its modification.
  • a dual agonist oxyntomodulin is prepared by substituting L-serine with D-serine at position 2 of oxyntomodulin to increase a resistance to dipeptidyl peptidase-IV (DPP-IV) and by attaching a cholesterol moiety at the C-terminal to increase the blood half-life at the same time.
  • DPP-IV dipeptidyl peptidase-IV
  • ZP2929 (Zealand) is prepared by substituting L-serine with D-serine at position 2 to enhance resistance to DPP-IV, substituting arginine with alanine at position 17 to enhance resistance to protease, substituting methionine with lysine at position 27 to enhance oxidative stability, and substituting glutamine with aspartic acid and alanine at positions 20 and 24 and asparagine with serine at position 28 to enhance deamidation stability.
  • oxyntomodulin (Merck) was enhanced to show half-life 8 ⁇ 12 minutes longer than the native oxyntomodulin, it still has a very short in vivo half-life of 1.7 hr and its administration dose is also as high as several mg/kg.
  • oxyntomodulin or derivatives thereof have disadvantages of daily administration of high dose due to the short half-life and low efficacy.
  • the present inventors have developed an oxyntomodulin derivative prepared by modifying the amino acid sequence of native oxyntomodulin in order to enhance its therapeutic effects on obesity and to reduce its administration dose. As a result, they found that the oxyntomodulin derivative shows more excellent activities on a glucagon receptor and a GLP-1 receptor than native oxyntomodulin, thereby completing the present invention.
  • An object of the present invention is to provide a novel peptide showing excellent therapeutic effects on obesity.
  • Another object of the present invention is to provide a composition for the prevention or treatment of obesity, comprising the peptide.
  • Still another object of the present invention is to provide a method for preventing or treating obesity by administering the peptide or the composition to a subject.
  • Still another object of the present invention is to provide use of the peptide in the preparation of drugs for the prevention or treatment of obesity.
  • the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, and also shows excellent receptor-activating effects. Thus, it can be widely used in the treatment of obesity with safety and efficacy.
  • FIG. 1 is a graph showing changes in food intake according to administration dose of oxyntomodulin or oxyntomodulin derivative.
  • the present invention provides a novel peptide including the amino acid sequence of the following Formula 1.
  • R1 is histidine, desamino-histidyl, dimethyl-histidyl (N-dimethyl-histidyl), beta-hydroxyimidazopropionyl, 4-imidazoacetyl, beta-carboxy imidazopropionyl or tyrosine;
  • X1 is Aib(aminoisobutyric acid), d-alanine, glycine, Sar(N-methylglycine), serine, or d-serine;
  • X2 is glutamic acid or glutamine
  • X3 is leucine or tyrosine
  • X4 is serine or alanine
  • X5 is lysine or arginine
  • X6 is glutamine or tyrosine
  • X7 is leucine or methionine
  • X8 is aspartic acid or glutamic acid
  • X9 is glutamic acid, serine, alpha-methyl-glutamic acid or is deleted
  • X10 is glutamine, glutamic acid, lysine, arginine, serine or is deleted;
  • X11 is alanine, arginine, valine or is deleted
  • X12 is alanine, arginine, serine, valine or is deleted
  • X13 is lysine, glutamine, arginine, alpha-methyl-glutamic acid or is deleted;
  • X14 is aspartic acid, glutamic acid, leucine or is deleted
  • X15 is phenylalanine or is deleted
  • X16 is isoleucine, valine or is deleted
  • X17 is alanine, cysteine, glutamic acid, lysine, glutamine, alpha-methyl-glutamic acid or is deleted;
  • X18 is tryptophan or is deleted
  • X19 is alanine, isoleucine, leucine, serine, valine or is deleted;
  • X20 is alanine, lysine, methionine, glutamine, arginine or is deleted;
  • X21 is asparagine or is deleted
  • X22 is alanine, glycine, threonine or is deleted
  • X23 is cysteine, lysine or is deleted
  • X24 is a peptide having 2 to 10 amino acids consisting of combinations of alanine, glycine and serine, or is deleted;
  • R2 is KRNRNNIA (SEQ ID NO. 32), GPSSGAPPPS (SEQ ID NO. 33), GPSSGAPPPSK (SEQ ID NO. 34), HSQGTFTSDYSKYLD (SEQ ID NO. 35), HSQGTFTSDYSRYLDK (SEQ ID NO. 36), HGEGTFTSDLSKQMEEEAVK (SEQ ID NO. 37) or is deleted (excluded if the amino acid sequence of Formula 1 is identical to that of SEQ ID NO. 1).
  • the term "peptide” means a compound of two or more ⁇ -amino acids linked by a peptide bond. With respect to the objects of the present invention, it means a peptide that activates both the GLP-1 receptor and the glucagon receptor to show anti-obesity effects.
  • the peptide according to the present invention includes peptides, peptide derivatives or peptide mimetics that are prepared by addition, deletion or substitution of amino acids of oxyntomodulin so as to activate both of the GLP-1 receptor and the glucagon receptor at a high level, compared to the native oxyntomodulin.
  • the peptide encompasses any peptide that is prepared by substitutions, additions, deletions or post translational modifications (e.g., methylation, acylation, ubiquitination, intramolecular covalent bonding) in the amino acid sequence of oxyntomodulin (HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA, SEQ ID NO. 1) so as to activate the glucagon and GLP-1 receptors at the same time.
  • substitution or addition of amino acids any of the 20 amino acids commonly found in human proteins, as well as atypical or non-naturally occurring amino acids can be used.
  • atypical amino acids include Sigma-Aldrich, ChemPep Inc., and Genzyme Pharmaceuticals.
  • the peptides including these amino acids and atypical peptide sequences may be synthesized and purchased from commercial suppliers, for example, American Peptide Company or Bachem (USA) or Anygen (Korea).
  • the peptide of the present invention may be substituted with 4-imidazoacetyl where the alpha carbon of histidine at position 1 of amino acid sequence represented by SEQ ID NO.
  • GLP-1 receptor-binding region may be substituted with amino acids that enhance hydrophobic and ionic bonds or combinations thereof.
  • a part of the oxyntomodulin sequence may be substituted with the amino acid sequence of GLP-1 or Exendin-4 to enhance the activity on GLP-1 receptor.
  • a part of the oxyntomodulin sequence may be substituted with a sequence stabilizing alpha helix.
  • amino acids at positions 10, 14, 16, 20, 24 and 28 of the amino acid sequence of Formula 1 may be substituted with amino acids or amino acid derivatives consisting of Tyr(4-Me), Phe, Phe(4-Me), Phe(4-Cl), Phe(4-CN), Phe(4-NO 2 ), Phe(4-NH 2 ), Phg, Pal, Nal, Ala(2-thienyl) and Ala(benzothienyl) that are known to stabilize alpha helix, and there are no limitations on the type and number of alpha helix-stabilizing amino acid or amino acid derivatives to be inserted.
  • amino acids at positions 10 and 14, 12 and 16, 16 and 20, 20 and 24, and 24 and 28 may be also substituted with glutamic acid or lysine, respectively so as to form rings, and there is no limitation on the number of rings to be inserted.
  • the peptide may be a peptide having an amino acid sequence selected from the following Formulae 2 to 6.
  • the peptide of the present invention is an oxyntomodulin derivative including the amino acid sequence of the following Formula 2 where the amino acid sequence of oxyntomodulin is substituted with that of exendin or GLP-1.
  • the peptide of the present invention is an oxyntomodulin derivative including the amino acid sequence of the following Formula 3, which is prepared by linking a part of the amino acid sequence of oxyntomodulin and a part of the amino acid sequence of exendin or GLP-1 via a proper amino acid linker.
  • the peptide of the present invention is an oxyntomodulin derivative including the amino acid sequence of the following Formula 4, wherein a part of the amino acid sequence of oxyntomodulin is substituted with an amino acid capable of enhancing the binding affinity to GLP-1 receptor, for example, Leu at position 26 which binds with GLP-1 receptor by hydrophobic interaction is substituted with the hydrophobic residue, Ile or Val.
  • the peptide of the present invention is an oxyntomodulin derivative including the following Formula 5, wherein a part of the amino acid sequence is deleted, added, or substituted with other amino acid in order to enhance the activities of native oxyntomodulin on GLP-1 receptor and glucagon receptor.
  • R1 is the same as in the description of Formula 1;
  • A is selected from the group consisting of SQGTFTSDYSKYLDSRRAQDFVQWLMNT (SEQ ID NO. 38), SQGTFTSDYSKYLDEEAVRLFIEWLMNT (SEQ ID NO. 39), SQGTFTSDYSKYLDERRAQDFVAWLKNT (SEQ ID NO. 40), GQGTFTSDYSRYLEEEAVRLFIEWLKNG (SEQ ID NO. 41), GQGTFTSDYSRQMEEEAVRLFIEWLKNG (SEQ ID NO. 42), GEGTFTSDLSRQMEEEAVRLFIEWAA (SEQ ID NO. 43), and SQGTFTSDYSRQMEEEAVRLFIEWLMNG (SEQ ID NO. 44);
  • SQGTFTSDYSKYLDSRRAQDFVQWLMNT SEQ ID NO. 38
  • SQGTFTSDYSKYLDEEAVRLFIEWLMNT SEQ ID NO. 39
  • SQGTFTSDYSKYLDERRAQDFVAWLKNT SEQ ID NO. 40
  • GQGTFTSDYSRYLEEEAVRLFIEWLKNG SEQ ID NO. 41
  • GQGTFTSDYSRQMEEEAVRLFIEWLKNG SEQ ID NO. 42
  • GEGTFTSDLSRQMEEEAVRLFIEWAA SEQ ID NO. 43
  • SQGTFTSDYSRQMEEEAVRLFIEWLMNG SEQ ID NO. 44
  • GEGTFTSDLSRQMEEEAVRLFIEW SEQ ID NO. 45
  • SQGTFTSDYSRYLD SEQ ID NO. 46
  • C is a peptide having 2 to 10 amino acids consisting of combinations of alanine, glycine and serine;
  • D1 is serine, glutamic acid or arginine
  • D2 is arginine, glutamic acid or serine
  • D3 is arginine, alanine or valine
  • D4 is arginine, valine or serine
  • D5 is glutamine, arginine or lysine
  • D6 is isoleucine, valine or serine
  • D7 is methionine, arginine or glutamine
  • D8 is threonine, glycine or alanine
  • E1 is serine, Aib, Sar, d-alanine or d-serine;
  • E2 is serine or glutamic acid
  • E3 is arginine or lysine
  • E4 is glutamine or lysine
  • E5 is aspartic acid or glutamic acid
  • E6 is glutamine, cysteine or lysine
  • E7 is cysteine, lysine or is deleted
  • R3 is KRNRNNIA (SEQ ID NO. 32), GPSSGAPPPS (SEQ ID NO. 33) or GPSSGAPPPSK (SEQ ID NO. 34);
  • R4 is HSQGTFTSDYSKYLD (SEQ ID NO. 35), HSQGTFTSDYSRYLDK (SEQ ID NO. 36) or HGEGTFTSDLSKQMEEEAVK (SEQ ID NO. 37); and,
  • R5 is KRNRNNIA (SEQ ID NO. 32), GPSSGAPPPS (SEQ ID NO. 33), GPSSGAPPPSK (SEQ ID NO. 34) or is deleted (excluded if the amino acid sequences of Formula 2 to 5 are identical to that of SEQ ID NO. 1).
  • novel peptide of the present invention may be a peptide of the following Formula 6.
  • R1 is histidine, desamino-histidyl, 4-imidazoacetyl or tyrosine;
  • X1 is Aib(aminoisobutyric acid), glycine or serine;
  • X2 is glutamic acid or glutamine
  • X3 is leucine or tyrosine
  • X4 is serine or alanine
  • X5 is lysine or arginine
  • X6 is glutamine or tyrosine
  • X7 is leucine or methionine
  • X8 is aspartic acid or glutamic acid
  • X9 is glutamic acid, alpha-methyl-glutamic acid or is deleted
  • X10 is glutamine, glutamic acid, lysine, arginine or is deleted;
  • X11 is alanine, arginine or is deleted
  • X12 is alanine, valine or is deleted
  • X13 is lysine, glutamine, arginine, alpha-methyl-glutamic acid or is deleted;
  • X14 is aspartic acid, glutamic acid, leucine or is deleted
  • X15 is phenylalanine or is deleted
  • X16 is isoleucine, valine or is deleted
  • X17 is alanine, cysteine, glutamic acid, glutamine, alpha-methyl-glutamic acid or is deleted;
  • X18 is tryptophan or is deleted
  • X19 is alanine, isoleucine, leucine, valine or is deleted;
  • X20 is alanine, lysine, methionine, arginine or is deleted;
  • X21 is asparagine or is deleted
  • X22 is threonine or is deleted
  • X23 is cysteine, lysine or is deleted
  • X24 is a peptide having 2 to 10 amino acids consisting of glycine or is deleted.
  • R2 is KRNRNNIA (SEQ ID NO. 32), GPSSGAPPPS (SEQ ID NO. 33), GPSSGAPPPSK (SEQ ID NO. 34), HSQGTFTSDYSKYLD (SEQ ID NO. 35), HSQGTFTSDYSRYLDK (SEQ ID NO. 36), HGEGTFTSDLSKQMEEEAVK (SEQ ID NO. 37) or is deleted (excluded if the amino acid sequence of Formula 6 is identical to that of SEQ ID NO. 1).
  • the peptide of the present invention may be selected from the group consisting of the peptides of SEQ ID NOs. 1 to 31. Much more preferably, the peptide of the present invention may be an oxyntomodulin derivative described in Table 1 of Example 2-1.
  • Oxyntomodulin has activities of two peptides, GLP-1 and glucagon.
  • GLP-1 decreases blood glucose, reduces food intake, and suppresses gastric emptying
  • glucagon increases blood glucose, facilitate lipolysis and decreases body-weight by increasing energy metabolisms.
  • Different biological effects of two peptides can cause undesired effects like increasing blood glucose if glucagon shows more dominant effect than GLP-1, or causing nausea and vomiting if GLP-1 shows more dominant effect than glucagon.
  • the oxyntomodulin derivatives of the present invention are not only aimed to increase these activities, for example, amino acids at position 1 and 11 of oxyntomodulin which suppress the activity of glucagon, may be modified for balancing the activity ratios of glucagon and GLP-1.
  • the present inventors performed in vitro experiments to demonstrate that the peptide of the present invention shows excellent activities on the GLP-1 receptor and the glucagon receptor, compared to oxyntomodulin. Thus, it is suggested that the peptide of the present invention activates the GLP-1 receptor and the glucagon receptor to show more excellent therapeutic effects on obesity than the conventional oxyntomodulin. In addition, its inhibitory effects on in vivo food intake were examined, and it shows more excellent inhibitory effects on food intake than the conventional oxyntomodulin (FIG. 1).
  • the modified oxyntomodulin derivatives of the present invention are also included in the scope of the present invention.
  • the present invention provides a polynucleotide encoding the peptide.
  • the term "homology”, as used herein for the polynucleotide, indicates sequence similarity between wild-type amino acid sequences or wild-type nucleotide sequences, and includes a gene sequence that is 75% or higher, preferably 85% or higher, more preferably 90% or higher and even more preferably 95% or higher identical to the polynucleotide sequence encoding the peptide.
  • the homology evaluation may be done with the naked eye or using a commercially available program. Using a commercially available computer program, the homology between two or more sequences may be expressed as a percentage (%), and the homology (%) between adjacent sequences may be evaluated.
  • the polynucleotide encoding the peptide is inserted into a vector and expressed so as to obtain a large amount of the peptide.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of obesity comprising the peptide.
  • prevention means all of the actions by which the occurrence of obesity is restrained or retarded by administration of the peptide or the composition
  • treatment means all of the actions by which the symptoms of obesity have taken a turn for the better or been modified favorably by administration of the peptide or the composition.
  • the term "administration" means introduction of an amount of a predetermined substance into a patient by a certain suitable method.
  • the composition of the present invention may be administered via any of the common routes, as long as it is able to reach a desired tissue, for example, but is not limited to, intraperitoneal, intravenous, intramuscular, subcutaneous, intradermal, oral, topical, intranasal, intrapulmonary, or intrarectal administration.
  • active ingredients of a composition for oral administration should be coated or formulated for protection against degradation in the stomach.
  • the term "obesity” implies accumulation of an excess amount of adipose tissue in the body, and a body mass index (body weight (kg) divided by the square of the height (m)) above 25 is to be regarded as obesity.
  • Obesity is usually caused by an energy imbalance, when the amount of dietary intake exceeds the amount of energy expended for a long period of time.
  • Obesity is a metabolic disease that affects the whole body, and increases the risk for diabetes, hyperlipidemia, sexual dysfunction, arthritis, and cardiovascular diseases, and in some cases, is associated with incidence of cancer.
  • the pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier, excipient, or diluent.
  • a pharmaceutically acceptable carrier such as a pharmaceutically acceptable styrene, aminobutyl styrene, aminobutyl sulfate, aminobutyl sulfate, aminobutyl sulfate, aminobutyl sulfate, a pharmaceutically acceptable containing pharmaceutically acceptable a pharmaceutically acceptable containing pharmaceutically acceptable a pharmaceutically acceptable a pharmaceutically acceptable containing a pharmaceutically acceptable a pharmaceutically acceptable styrene, styrene, styrene, styrene, sulfate, aminobutyl, sulfate, aminobutyl sulfate, aminobutyl sulfate, aminobutyl sulfate, aminobutyl,
  • the pharmaceutical composition including the derivative of the present invention may further include a pharmaceutically acceptable carrier.
  • the carrier may include, but is not limited to, a binder, a lubricant, a disintegrant, an excipient, a solubilizer, a dispersing agent, a stabilizer, a suspending agent, a colorant, and a flavorant.
  • the carrier may include a buffering agent, a preserving agent, an analgesic, a solubilizer, an isotonic agent, and a stabilizer.
  • the carrier may include a base, an excipient, a lubricant, and a preserving agent.
  • composition of the present invention may be formulated into a variety of dosage forms in combination with the aforementioned pharmaceutically acceptable carriers.
  • the pharmaceutical composition may be formulated into tablets, troches, capsules, elixirs, suspensions, syrups or wafers.
  • the pharmaceutical composition may be formulated into an ampule as a single dosage form or a multidose container.
  • the pharmaceutical composition may also be formulated into solutions, suspensions, tablets, pills, capsules and long-acting preparations.
  • examples of the carrier, the excipient, and the diluent suitable for the pharmaceutical formulations include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oils.
  • the pharmaceutical formulations may further include fillers, anti-coagulating agents, lubricants, humectants, flavorants, and antiseptics.
  • the pharmaceutical composition of the present invention may have any formulation selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquids for internal use, emulsions, syrups, sterile aqueous solutions, non-aqueous solvents, lyophilized formulations and suppositories.
  • composition may be formulated into a single dosage form suitable for the patient's body, and preferably is formulated into a preparation useful for peptide drugs according to the typical method in the pharmaceutical field so as to be administered by an oral or parenteral route such as through skin, intravenous, intramuscular, intra-arterial, intramedullary, intramedullary, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, intracolonic, topical, sublingual, vaginal, or rectal administration, but is not limited thereto.
  • an oral or parenteral route such as through skin, intravenous, intramuscular, intra-arterial, intramedullary, intramedullary, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, intracolonic, topical, sublingual, vaginal, or rectal administration, but is not limited thereto.
  • the peptide may be used by blending with a variety of pharmaceutically acceptable carriers such as physiological saline or organic solvents.
  • pharmaceutically acceptable carriers such as physiological saline or organic solvents.
  • carbohydrates such as glucose, sucrose or dextrans, antioxidants such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers may be used.
  • the administration dose and frequency of the pharmaceutical composition of the present invention are determined by the type of active ingredient, together with various factors such as the disease to be treated, administration route, patient's age, gender, and body weight, and disease severity.
  • the total effective dose of the composition of the present invention may be administered to a patient in a single dose, or may be administered for a long period of time in multiple doses according to a fractionated treatment protocol.
  • the content of active ingredient may vary depending on the disease severity.
  • the total daily dose of the peptide of the present invention may be approximately 0.0001 ⁇ g to 500 mg per 1 kg of body weight of a patient.
  • the effective dose of the peptide is determined considering various factors including patient's age, body weight, health conditions, gender, disease severity, diet, and secretion rate, in addition to administration route and treatment frequency of the pharmaceutical composition.
  • the pharmaceutical composition according to the present invention is not particularly limited to the formulation, and administration route and mode, as long as it shows the effects of the present invention.
  • the pharmaceutical composition of the present invention shows excellent in-vivo duration of efficacy and titer, thereby remarkably reducing the number and frequency of administration thereof.
  • the pharmaceutical composition may be administered alone or in combination or coincident with other pharmaceutical formulations showing prophylactic or therapeutic effects on obesity.
  • the pharmaceutical formulations showing prophylactic or therapeutic effects on obesity are not particularly limited, and may include a GLP-1 receptor agonist, a leptin receptor agonist, a DPP-IV inhibitor, a Y5 receptor antagonist, a Melanin-concentrating hormone (MCH) receptor antagonist, a Y2/3 receptor agonist, a MC3/4 receptor agonist, a gastric/pancreatic lipase inhibitor, a 5HT2c agonist, a ⁇ 3A receptor agonist, an Amylin receptor agonist, a Ghrelin antagonist, and/or a Ghrelin receptor antagonist.
  • MCH Melanin-concentrating hormone
  • the present invention provides a method for preventing or treating obesity, comprising the step of administering to a subject the peptide or the pharmaceutical composition including the same.
  • the term "subject" is those suspected of having obesity, which means mammals including human, mouse, and livestock having obesity or having the possibility of obesity.
  • any subject to be treated with the peptide or the pharmaceutical composition of the present invention is included without limitation.
  • the pharmaceutical composition including the peptide of the present invention is administered to a subject suspected of having obesity, thereby treating the subject effectively.
  • the obesity is as described above.
  • the therapeutic method of the present invention may include the step of administering the composition including the peptide at a pharmaceutically effective amount.
  • the total daily dose should be determined through appropriate medical judgment by a physician, and administered once or several times.
  • the specific therapeutically effective dose level for any particular patient may vary depending on various factors well known in the medical art, including the kind and degree of the response to be achieved, concrete compositions according to whether other agents are used therewith or not, the patient’s age, body weight, health condition, gender, and diet, the time and route of administration, the secretion rate of the composition, the time period of therapy, other drugs used in combination or coincident with the composition of this invention, and like factors well known in the medical arts.
  • the present invention provides a use of the peptide or the pharmaceutical composition including the same in the preparation of drugs for the prevention or treatment of obesity.
  • Example 1-1 Production of cell line showing cAMP response to GLP-1
  • PCR was performed using a region corresponding to ORF (Open Reading Frame) in cDNA (OriGene Technologies, Inc. USA) of human GLP-1 receptor gene as a template, and the following forward and reverse primers including each of the HindIII and EcoRI restriction sites so as to obtain a PCR product.
  • ORF Open Reading Frame
  • Reverse primer 5'-GAACGGTCCGGAGGACGTCGACTCTTAAGATAG-3'(SEQ ID NO. 48)
  • the PCR product was cloned into the known animal cell expression vector x0GC/dhfr to prepare a recombinant vector x0GC/GLP1R.
  • CHO DG44 cell line cultured in DMEM/F12 (10% FBS) medium was transfected with the recombinant vector x0GC/GLP1R using Lipofectamine (Invitrogen, USA), and cultured in a selection medium containing 1 mg/mL G418 and 10 nM methotraxate.
  • Single clone cell lines were selected therefrom by a limit dilution technique, and a cell line showing excellent cAMP response to GLP-1 in a concentration-dependent manner was finally selected therefrom.
  • Example 1-2 Production of cell line showing cAMP response to glucagon
  • PCR was performed using a region corresponding to ORF in cDNA (OriGene Technologies, Inc. USA) of human glucagon receptor gene as a template, and the following forward and reverse primers including each of the EcoRI and XhoI restriction sites so as to obtain a PCR product.
  • Reverse primer 5'-CTAACCGACTCTCGGGGAAGACTGAGCTCGCC-3'(SEQ ID NO. 50)
  • the PCR product was cloned into the known animal cell expression vector x0GC/dhfr to prepare a recombinant vector x0GC/GCGR.
  • CHO DG44 cell line cultured in DMEM/F12 (10% FBS) medium was transfected with the recombinant vector x0GC/GCGR using Lipofectamine, and cultured in a selection medium containing 1 mg/mL G418 and 10 nM methotraxate.
  • Single clone cell lines were selected therefrom by a limit dilution technique, and a cell line showing excellent cAMP response to glucagon in a concentration-dependent manner was finally selected therefrom.
  • oxyntomodulin derivatives having the following amino acid sequences were synthesized (Table 1).
  • Oxyntomodulin and oxyntomodulin derivatives SEQ ID NO .
  • Amino acid sequence SEQ ID NO. 1 HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA SEQ ID NO. 2 CA-SQGTFTSDYSKYLDEEAVRLFIEWLMNTKRNRNNIA SEQ ID NO. 3 CA-SQGTFTSDYSKYLDERRAQDFVAWLKNTGPSSGAPPPS SEQ ID NO. 4 CA-GQGTFTSDYSRYLEEEAVRLFIEWLKNGGPSSGAPPPS SEQ ID NO. 5 CA-GQGTFTSDYSRQMEEEAVRLFIEWLKNGGPSSGAPPPS SEQ ID NO.
  • CA-SQGTFTSDYSRYLDEEAVRLFIEWIRNGGPSSGAPPPSK SEQ ID NO. 19
  • CA-SQGTFTSDYSRYLD EAV K LFIEWIRNTKRNRNNIA
  • CA-SQGTFTSDYSRYLD EAV K LFIEWIRNGGPSSGAPPPSK
  • SEQ ID NO. 21 CA-SQGTFTSDYSRQLEEEAVRLFIEWVRNTKRNRNNIA
  • DA-SQGTFTSDYSKYLD E KRA K EFVQWLMNTK SEQ ID NO. 23
  • HAibQGTFTSDYSKYLDEKRAKEFVCWLMNT SEQ ID NO.
  • HAibQGTFTSDYSKYLDEKRAKEFVQWLMNTC SEQ ID NO. 25 HAibQGTFTSDYSKYLD E KRA K EFVQWLMNTC SEQ ID NO. 26 HAibQGTFTSDYS K YLD E KRAKEFVQWLMNTC SEQ ID NO. 27 HAibQGTFTSDYSKYLD E QAA K EFICWLMNT SEQ ID NO. 28 HAibQGTFTSDYSKYLDEKRAKEFVQWLMNT SEQ ID NO. 29 CA-AibQGTFTSDYSKYLD E KRA K EFVQWLMNTC SEQ ID NO. 30 HAibQGTFTSDYAKYLD E KRA K EFVQWLMNTC SEQ ID NO. 31 YAibQGTFTSDYSKYLD E KRA K EFVQWLMNTC
  • amino acids in bold and underlined represent ring formation
  • amino acids represented by X mean a non-native amino acid, alpha-methyl-glutamic acid.
  • CA represents 4-imidazoacetyl
  • DA represents desamino-histidyl.
  • Example 2-2 Test on in vitro activity of oxyntomodulin derivatives
  • Example 2-1 In order to measure anti-obesity efficacies of the oxyntomodulin derivatives synthesized in Example 2-1, cell activity was measured in vitro using the cell lines prepared in Examples 1-1 and 1-2.
  • the cell lines were those prepared by transfecting CHO (Chinese Hamster Ovary) to express human GLP-1 receptor gene and glucagon receptor gene, respectively. Thus, they are suitable to measure GLP-1 and glucagon activities. Therefore, the activity of each oxyntomodulin derivative was measured using each transformed cell line.
  • each cell line was sub-cultured twice or three time a week, and aliquoted in each well of a 96-well plate at a density of 1 X 10 5 , followed by cultivation for 24 hours.
  • the cultured cells were washed with KRB buffer and suspended in 40 ml of KRB buffer containing 1 mM IBMX, and left at room temperature for 5 minutes.
  • Oxyntomodulin (SEQ ID NO. 1) and oxyntomodulin derivatives represented by SEQ ID NOs. 2-6, 8, 10-13, 17, 18, 23-25, 27-30 and 31) were diluted from 1000 nM to 0.02 nM by 5-fold serial dilution, and each 40 mL thereof was added to the cells, and cultured at 37°C for 1 hour in a CO2 incubator.
  • EC 50 values were calculated therefrom, and compared to each other. EC 50 values are shown in the following Table 2.
  • oxyntomodulin activates both the GLP-1 receptor and glucagon receptor to suppress appetite, facilitate lipolysis, and promote satiety, thereby showing anti-obesity effects.
  • the oxyntomodulin derivatives according to the present invention show higher in vitro activities on both the GLP-1 receptor and glucagon receptor than the wild-type oxyntomodulin, and therefore can be used as a therapeutic agent for obesity with higher efficacies than the known oxyntomodulin.
  • FIG. 1 is a graph showing changes in food intake according to administration dose of oxyntomodulin or oxyntomodulin derivative. As shown in FIG. 1, administration of 1 mg/kg of oxyntomodulin derivative showed more excellent inhibitory effects on food intake than administration of 10 mg/kg of oxyntomodulin.
  • the oxyntomodulin derivatives of the present invention have much higher anti-obesity effects than the wild-type oxyntomodulin, even though administered at a lower dose, indicating improvement in the problems of the wild-type oxyntomodulin that shows lower anti-obesity effects and should be administered at a high dose three times a day.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis with reduced side-effects, and also shows excellent receptor-activating effects. Thus, it can be widely used in the treatment of obesity with safety and efficacy.

Description

NOVEL OXYNTOMODULIN DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY COMPRISING THE SAME
The present invention relates to a novel peptide showing excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor greater than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient.
Recently, economic growth and changes in lifestyle are leading to changes in eating habits. The main causes of rising overweight and obesity rates in contemporary people are consumption of high-calorie foods such as fast foods and lack of exercise. World Health Organization (WHO) estimates that more than 1 billion people worldwide are overweight and at least 300 million of them are clinically obese. In particular, 250,000 people die each year in Europe and more than 2.5 million people worldwide die each year as a result of being overweight (World Health Organization, Global Strategy on Diet, Physical Activity and Health, 2004).
Being overweight and obese increases blood pressure and cholesterol levels to cause occurrence or exacerbation of various diseases such as cardiovascular disease, diabetes, and arthritis, and are also main causes of rising incidence rates of arteriosclerosis, hypertension, hyperlipidemia or cardiovascular disease in children or adolescents as well as in adults.
Obesity is a severe condition that causes various diseases worldwide. It is thought to be overcome by individual efforts, and it is also believed that obese patients lack self-control. However, it is difficult to treat obesity, because obesity is a complex disorder involving appetite regulation and energy metabolism. For the treatment of obesity, abnormal actions associated with appetite regulation and energy metabolism should be treated together with efforts of obese patients. Many attempts have been made to develop drugs capable of treating the abnormal actions. As the result of these efforts, drugs such as Rimonabant (Sanofi-Aventis), Sibutramin (Abbott), Contrave (Takeda), and Orlistat (Roche) have been developed, but they have the disadvantages of serious adverse effects or very weak anti-obesity effects. For example, it was reported that Rimonabant (Sanofi-Aventis) shows a side-effect of central nerve disorder, Sibutramine (Abbott) and Contrave (Takeda) show cardiovascular side-effects, and Orlistat (Roche) shows only 4 kg of weight loss when taken for 1 year. Unfortunately, there are no therapeutic agents for obesity which can be safely prescribed for obese patients.
Many studies have been made to develop therapeutic agents for obesity which do not have the problems of the conventional anti-obesity drugs. Recently, glucagon derivatives have received much attention. Glucagon is produced by the pancreas when the level of glucose in the blood drops resulting from other medications or diseases, hormone or enzyme deficiencies. Glucagon stimulates glycogen breakdown in the liver, and facilitates glucose release to raise blood glucose levels to a normal range. In addition to the effect of increasing the blood glucose level, glucagon suppresses appetite and activates hormone-sensitive lipase(HSL) of adipocytes to facilitate lipolysis, thereby showing anti-obesity effects. One of the glucagon derivatives, glucagon like peptide-1 (GLP-1) is under development as a therapeutic agent for hyperglycemia in patients with diabetes, and it functions to stimulate insulin synthesis and secretion, to inhibit glucagon secretion, to slow gastric emptying, to increase glucose utilization, and to inhibit food intake. Exendin-4 is isolated from lizard venom that shares approximately 50% amino acid homology with GLP-1 and is also reported to activate the GLP-1 receptor, thereby ameliorating hyperglycemia in patients with diabetes. However, anti-obesity drugs including GLP-1 are reported to show side-effects such as vomiting and nausea.
As an alternative to GLP-1, therefore, much attention has been focused on oxyntomodulin, a peptide derived from a glucagon precursor, pre-glucagon that binds to the receptors of two peptides, GLP-1 and glucagon. Oxyntomodulin represents a potent anti-obesity therapy, because it inhibits food intake like GLP-1, promotes satiety, and has a lipolytic activity like glucagon.
Based on the dual function of the oxyntomodulin peptide, it has been actively studied as a drug for the treatment of obesity. For example, Korean Patent No. 925017 discloses a pharmaceutical composition including oxyntomodulin as an active ingredient for the treatment of overweight human, which is administered via an oral, parenteral, mucosal, rectal, subcutaneous, or transdermal route. However, it has been reported that this anti-obesity drug including oxyntomodulin has a short in vivo half-life and weak therapeutic efficacy, even though administered at a high dose three times a day. Thus, many efforts have been made to improve the in vivo half-life or therapeutic effect of oxyntomodulin on obesity by its modification.
For example, a dual agonist oxyntomodulin (Merck) is prepared by substituting L-serine with D-serine at position 2 of oxyntomodulin to increase a resistance to dipeptidyl peptidase-IV (DPP-IV) and by attaching a cholesterol moiety at the C-terminal to increase the blood half-life at the same time. ZP2929 (Zealand) is prepared by substituting L-serine with D-serine at position 2 to enhance resistance to DPP-IV, substituting arginine with alanine at position 17 to enhance resistance to protease, substituting methionine with lysine at position 27 to enhance oxidative stability, and substituting glutamine with aspartic acid and alanine at positions 20 and 24 and asparagine with serine at position 28 to enhance deamidation stability. However, even though the half-life of the dual agonist oxyntomodulin (Merck) was enhanced to show half-life 8~12 minutes longer than the native oxyntomodulin, it still has a very short in vivo half-life of 1.7 hr and its administration dose is also as high as several mg/kg. Unfortunately, oxyntomodulin or derivatives thereof have disadvantages of daily administration of high dose due to the short half-life and low efficacy.
Accordingly, the present inventors have developed an oxyntomodulin derivative prepared by modifying the amino acid sequence of native oxyntomodulin in order to enhance its therapeutic effects on obesity and to reduce its administration dose. As a result, they found that the oxyntomodulin derivative shows more excellent activities on a glucagon receptor and a GLP-1 receptor than native oxyntomodulin, thereby completing the present invention.
An object of the present invention is to provide a novel peptide showing excellent therapeutic effects on obesity.
Another object of the present invention is to provide a composition for the prevention or treatment of obesity, comprising the peptide.
Still another object of the present invention is to provide a method for preventing or treating obesity by administering the peptide or the composition to a subject.
Still another object of the present invention is to provide use of the peptide in the preparation of drugs for the prevention or treatment of obesity.
Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, and also shows excellent receptor-activating effects. Thus, it can be widely used in the treatment of obesity with safety and efficacy.
FIG. 1 is a graph showing changes in food intake according to administration dose of oxyntomodulin or oxyntomodulin derivative.
In one aspect to achieve the above objects, the present invention provides a novel peptide including the amino acid sequence of the following Formula 1.
R1-X1-X2-GTFTSD-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-X22-X23-X24-R2 (Formula 1)
wherein R1 is histidine, desamino-histidyl, dimethyl-histidyl (N-dimethyl-histidyl), beta-hydroxyimidazopropionyl, 4-imidazoacetyl, beta-carboxy imidazopropionyl or tyrosine;
X1 is Aib(aminoisobutyric acid), d-alanine, glycine, Sar(N-methylglycine), serine, or d-serine;
X2 is glutamic acid or glutamine;
X3 is leucine or tyrosine;
X4 is serine or alanine;
X5 is lysine or arginine;
X6 is glutamine or tyrosine;
X7 is leucine or methionine;
X8 is aspartic acid or glutamic acid;
X9 is glutamic acid, serine, alpha-methyl-glutamic acid or is deleted;
X10 is glutamine, glutamic acid, lysine, arginine, serine or is deleted;
X11 is alanine, arginine, valine or is deleted;
X12 is alanine, arginine, serine, valine or is deleted;
X13 is lysine, glutamine, arginine, alpha-methyl-glutamic acid or is deleted;
X14 is aspartic acid, glutamic acid, leucine or is deleted;
X15 is phenylalanine or is deleted;
X16 is isoleucine, valine or is deleted;
X17 is alanine, cysteine, glutamic acid, lysine, glutamine, alpha-methyl-glutamic acid or is deleted;
X18 is tryptophan or is deleted;
X19 is alanine, isoleucine, leucine, serine, valine or is deleted;
X20 is alanine, lysine, methionine, glutamine, arginine or is deleted;
X21 is asparagine or is deleted;
X22 is alanine, glycine, threonine or is deleted;
X23 is cysteine, lysine or is deleted;
X24 is a peptide having 2 to 10 amino acids consisting of combinations of alanine, glycine and serine, or is deleted; and
R2 is KRNRNNIA (SEQ ID NO. 32), GPSSGAPPPS (SEQ ID NO. 33), GPSSGAPPPSK (SEQ ID NO. 34), HSQGTFTSDYSKYLD (SEQ ID NO. 35), HSQGTFTSDYSRYLDK (SEQ ID NO. 36), HGEGTFTSDLSKQMEEEAVK (SEQ ID NO. 37) or is deleted (excluded if the amino acid sequence of Formula 1 is identical to that of SEQ ID NO. 1).
As used herein, the term "peptide" means a compound of two or more α-amino acids linked by a peptide bond. With respect to the objects of the present invention, it means a peptide that activates both the GLP-1 receptor and the glucagon receptor to show anti-obesity effects. The peptide according to the present invention includes peptides, peptide derivatives or peptide mimetics that are prepared by addition, deletion or substitution of amino acids of oxyntomodulin so as to activate both of the GLP-1 receptor and the glucagon receptor at a high level, compared to the native oxyntomodulin.
Amino acids mentioned herein are abbreviated according to the nomenclature rule of IUPAC-IUB as follows:
Alanine A Arginine R
Asparagine N Aspartic acid D
Cysteine C Glutamic acid E
Glutamine Q Glycine G
Histidine H Isoleucine I
Leucine L Lysine K
Methionine M Phenylalanine F
Proline P Serine S
Threonine T Tryptophan W
Tyrosine Y Valine V
In the present invention, the peptide encompasses any peptide that is prepared by substitutions, additions, deletions or post translational modifications (e.g., methylation, acylation, ubiquitination, intramolecular covalent bonding) in the amino acid sequence of oxyntomodulin (HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA, SEQ ID NO. 1) so as to activate the glucagon and GLP-1 receptors at the same time. Upon substitution or addition of amino acids, any of the 20 amino acids commonly found in human proteins, as well as atypical or non-naturally occurring amino acids can be used. Commercially available sources of atypical amino acids include Sigma-Aldrich, ChemPep Inc., and Genzyme Pharmaceuticals. The peptides including these amino acids and atypical peptide sequences may be synthesized and purchased from commercial suppliers, for example, American Peptide Company or Bachem (USA) or Anygen (Korea).
In order to enhance the activity of the wild-type oxyntomodulin for the glucagon receptor and the GLP-1 receptor, the peptide of the present invention may be substituted with 4-imidazoacetyl where the alpha carbon of histidine at position 1 of amino acid sequence represented by SEQ ID NO. 1 is deleted, desamino-histidyl where the N-terminal amino group is deleted, dimethyl-histidyl (N-dimethyl-histidyl) where the N-terminal amino group is modified with two methyl groups, beta-hydroxy imidazopropionyl where the N-terminal amino group is substituted with a hydroxyl group, or beta-carboxy imidazopropionyl where the N-terminal amino group is substituted with a carboxyl group. In addition, the GLP-1 receptor-binding region may be substituted with amino acids that enhance hydrophobic and ionic bonds or combinations thereof. A part of the oxyntomodulin sequence may be substituted with the amino acid sequence of GLP-1 or Exendin-4 to enhance the activity on GLP-1 receptor.
Further, a part of the oxyntomodulin sequence may be substituted with a sequence stabilizing alpha helix. Preferably, amino acids at positions 10, 14, 16, 20, 24 and 28 of the amino acid sequence of Formula 1 may be substituted with amino acids or amino acid derivatives consisting of Tyr(4-Me), Phe, Phe(4-Me), Phe(4-Cl), Phe(4-CN), Phe(4-NO2), Phe(4-NH2), Phg, Pal, Nal, Ala(2-thienyl) and Ala(benzothienyl) that are known to stabilize alpha helix, and there are no limitations on the type and number of alpha helix-stabilizing amino acid or amino acid derivatives to be inserted. Preferably, amino acids at positions 10 and 14, 12 and 16, 16 and 20, 20 and 24, and 24 and 28 may be also substituted with glutamic acid or lysine, respectively so as to form rings, and there is no limitation on the number of rings to be inserted. Most preferably, the peptide may be a peptide having an amino acid sequence selected from the following Formulae 2 to 6.
In one specific embodiment, the peptide of the present invention is an oxyntomodulin derivative including the amino acid sequence of the following Formula 2 where the amino acid sequence of oxyntomodulin is substituted with that of exendin or GLP-1.
R1-A-R3 (Formula 2)
In another specific embodiment, the peptide of the present invention is an oxyntomodulin derivative including the amino acid sequence of the following Formula 3, which is prepared by linking a part of the amino acid sequence of oxyntomodulin and a part of the amino acid sequence of exendin or GLP-1 via a proper amino acid linker.
R1-B-C-R4 (Formula 3)
In still another specific embodiment, the peptide of the present invention is an oxyntomodulin derivative including the amino acid sequence of the following Formula 4, wherein a part of the amino acid sequence of oxyntomodulin is substituted with an amino acid capable of enhancing the binding affinity to GLP-1 receptor, for example, Leu at position 26 which binds with GLP-1 receptor by hydrophobic interaction is substituted with the hydrophobic residue, Ile or Val.
R1-SQGTFTSDYSKYLD-D1-D2-D3-D4-D5-LFVQW-D6-D7-N-D8-R3 (Formula 4)
In still another specific embodiment, the peptide of the present invention is an oxyntomodulin derivative including the following Formula 5, wherein a part of the amino acid sequence is deleted, added, or substituted with other amino acid in order to enhance the activities of native oxyntomodulin on GLP-1 receptor and glucagon receptor.
R1-E1-QGTFTSDYSKYLD-E2-E3-RA-E4-E5-FV-E6-WLMNT-E7-R5 (Formula 5)
In Formulae 2 to 5, R1 is the same as in the description of Formula 1;
A is selected from the group consisting of SQGTFTSDYSKYLDSRRAQDFVQWLMNT (SEQ ID NO. 38), SQGTFTSDYSKYLDEEAVRLFIEWLMNT (SEQ ID NO. 39), SQGTFTSDYSKYLDERRAQDFVAWLKNT (SEQ ID NO. 40), GQGTFTSDYSRYLEEEAVRLFIEWLKNG (SEQ ID NO. 41), GQGTFTSDYSRQMEEEAVRLFIEWLKNG (SEQ ID NO. 42), GEGTFTSDLSRQMEEEAVRLFIEWAA (SEQ ID NO. 43), and SQGTFTSDYSRQMEEEAVRLFIEWLMNG (SEQ ID NO. 44);
B is selected from the group consisting of SQGTFTSDYSKYLDSRRAQDFVQWLMNT (SEQ ID NO. 38), SQGTFTSDYSKYLDEEAVRLFIEWLMNT (SEQ ID NO. 39), SQGTFTSDYSKYLDERRAQDFVAWLKNT (SEQ ID NO. 40), GQGTFTSDYSRYLEEEAVRLFIEWLKNG (SEQ ID NO. 41), GQGTFTSDYSRQMEEEAVRLFIEWLKNG (SEQ ID NO. 42), GEGTFTSDLSRQMEEEAVRLFIEWAA (SEQ ID NO. 43), SQGTFTSDYSRQMEEEAVRLFIEWLMNG (SEQ ID NO. 44), GEGTFTSDLSRQMEEEAVRLFIEW (SEQ ID NO. 45), and SQGTFTSDYSRYLD (SEQ ID NO. 46);
C is a peptide having 2 to 10 amino acids consisting of combinations of alanine, glycine and serine;
D1 is serine, glutamic acid or arginine;
D2 is arginine, glutamic acid or serine;
D3 is arginine, alanine or valine;
D4 is arginine, valine or serine;
D5 is glutamine, arginine or lysine;
D6 is isoleucine, valine or serine;
D7 is methionine, arginine or glutamine;
D8 is threonine, glycine or alanine;
E1 is serine, Aib, Sar, d-alanine or d-serine;
E2 is serine or glutamic acid;
E3 is arginine or lysine;
E4 is glutamine or lysine;
E5 is aspartic acid or glutamic acid;
E6 is glutamine, cysteine or lysine;
E7 is cysteine, lysine or is deleted;
R3 is KRNRNNIA (SEQ ID NO. 32), GPSSGAPPPS (SEQ ID NO. 33) or GPSSGAPPPSK (SEQ ID NO. 34);
R4 is HSQGTFTSDYSKYLD (SEQ ID NO. 35), HSQGTFTSDYSRYLDK (SEQ ID NO. 36) or HGEGTFTSDLSKQMEEEAVK (SEQ ID NO. 37); and,
R5 is KRNRNNIA (SEQ ID NO. 32), GPSSGAPPPS (SEQ ID NO. 33), GPSSGAPPPSK (SEQ ID NO. 34) or is deleted (excluded if the amino acid sequences of Formula 2 to 5 are identical to that of SEQ ID NO. 1).
Preferably, the novel peptide of the present invention may be a peptide of the following Formula 6.
R1-X1-X2-GTFTSD-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-X22-X23-X24-R2 (Formula 6)
wherein R1 is histidine, desamino-histidyl, 4-imidazoacetyl or tyrosine;
X1 is Aib(aminoisobutyric acid), glycine or serine;
X2 is glutamic acid or glutamine;
X3 is leucine or tyrosine;
X4 is serine or alanine;
X5 is lysine or arginine;
X6 is glutamine or tyrosine;
X7 is leucine or methionine;
X8 is aspartic acid or glutamic acid;
X9 is glutamic acid, alpha-methyl-glutamic acid or is deleted;
X10 is glutamine, glutamic acid, lysine, arginine or is deleted;
X11 is alanine, arginine or is deleted;
X12 is alanine, valine or is deleted;
X13 is lysine, glutamine, arginine, alpha-methyl-glutamic acid or is deleted;
X14 is aspartic acid, glutamic acid, leucine or is deleted;
X15 is phenylalanine or is deleted;
X16 is isoleucine, valine or is deleted;
X17 is alanine, cysteine, glutamic acid, glutamine, alpha-methyl-glutamic acid or is deleted;
X18 is tryptophan or is deleted;
X19 is alanine, isoleucine, leucine, valine or is deleted;
X20 is alanine, lysine, methionine, arginine or is deleted;
X21 is asparagine or is deleted;
X22 is threonine or is deleted;
X23 is cysteine, lysine or is deleted;
X24 is a peptide having 2 to 10 amino acids consisting of glycine or is deleted; and
R2 is KRNRNNIA (SEQ ID NO. 32), GPSSGAPPPS (SEQ ID NO. 33), GPSSGAPPPSK (SEQ ID NO. 34), HSQGTFTSDYSKYLD (SEQ ID NO. 35), HSQGTFTSDYSRYLDK (SEQ ID NO. 36), HGEGTFTSDLSKQMEEEAVK (SEQ ID NO. 37) or is deleted (excluded if the amino acid sequence of Formula 6 is identical to that of SEQ ID NO. 1).
More preferably, the peptide of the present invention may be selected from the group consisting of the peptides of SEQ ID NOs. 1 to 31. Much more preferably, the peptide of the present invention may be an oxyntomodulin derivative described in Table 1 of Example 2-1.
Oxyntomodulin has activities of two peptides, GLP-1 and glucagon. GLP-1 decreases blood glucose, reduces food intake, and suppresses gastric emptying, and glucagon increases blood glucose, facilitate lipolysis and decreases body-weight by increasing energy metabolisms. Different biological effects of two peptides can cause undesired effects like increasing blood glucose if glucagon shows more dominant effect than GLP-1, or causing nausea and vomiting if GLP-1 shows more dominant effect than glucagon. Therefore, the oxyntomodulin derivatives of the present invention are not only aimed to increase these activities, for example, amino acids at position 1 and 11 of oxyntomodulin which suppress the activity of glucagon, may be modified for balancing the activity ratios of glucagon and GLP-1.
The present inventors performed in vitro experiments to demonstrate that the peptide of the present invention shows excellent activities on the GLP-1 receptor and the glucagon receptor, compared to oxyntomodulin. Thus, it is suggested that the peptide of the present invention activates the GLP-1 receptor and the glucagon receptor to show more excellent therapeutic effects on obesity than the conventional oxyntomodulin. In addition, its inhibitory effects on in vivo food intake were examined, and it shows more excellent inhibitory effects on food intake than the conventional oxyntomodulin (FIG. 1).
It is apparent to those skilled in the art that when the oxyntomodulin derivatives of the present invention are modified using the typical techniques, including modification with polymers such as PEG and sugar chain or fusion with albumin, transferrin, fatty acid, and immunoglobulin in order to improve the therapeutic effects of the oxyntomodulin derivatives, they will show superior therapeutic effects to native oxyntomodulin. Therefore, the modified oxyntomodulin derivatives are also included in the scope of the present invention.
In another aspect, the present invention provides a polynucleotide encoding the peptide.
The term "homology", as used herein for the polynucleotide, indicates sequence similarity between wild-type amino acid sequences or wild-type nucleotide sequences, and includes a gene sequence that is 75% or higher, preferably 85% or higher, more preferably 90% or higher and even more preferably 95% or higher identical to the polynucleotide sequence encoding the peptide. The homology evaluation may be done with the naked eye or using a commercially available program. Using a commercially available computer program, the homology between two or more sequences may be expressed as a percentage (%), and the homology (%) between adjacent sequences may be evaluated. The polynucleotide encoding the peptide is inserted into a vector and expressed so as to obtain a large amount of the peptide.
In still another aspect, the present invention provides a pharmaceutical composition for the prevention or treatment of obesity comprising the peptide.
As used herein, the term "prevention" means all of the actions by which the occurrence of obesity is restrained or retarded by administration of the peptide or the composition, and the term "treatment" means all of the actions by which the symptoms of obesity have taken a turn for the better or been modified favorably by administration of the peptide or the composition.
As used herein, the term "administration" means introduction of an amount of a predetermined substance into a patient by a certain suitable method. The composition of the present invention may be administered via any of the common routes, as long as it is able to reach a desired tissue, for example, but is not limited to, intraperitoneal, intravenous, intramuscular, subcutaneous, intradermal, oral, topical, intranasal, intrapulmonary, or intrarectal administration. However, since peptides are digested upon oral administration, active ingredients of a composition for oral administration should be coated or formulated for protection against degradation in the stomach.
As used herein, the term "obesity" implies accumulation of an excess amount of adipose tissue in the body, and a body mass index (body weight (kg) divided by the square of the height (m)) above 25 is to be regarded as obesity. Obesity is usually caused by an energy imbalance, when the amount of dietary intake exceeds the amount of energy expended for a long period of time. Obesity is a metabolic disease that affects the whole body, and increases the risk for diabetes, hyperlipidemia, sexual dysfunction, arthritis, and cardiovascular diseases, and in some cases, is associated with incidence of cancer.
The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier, excipient, or diluent. As used herein, the term "pharmaceutically acceptable" means that the composition is sufficient to achieve the therapeutic effects without deleterious side effects, and may be readily determined depending on the type of the diseases, the patient's age, body weight, health conditions, gender, and drug sensitivity, administration route, administration mode, administration frequency, duration of treatment, drugs used in combination or coincident with the composition of this invention, and other factors known in medicine.
The pharmaceutical composition including the derivative of the present invention may further include a pharmaceutically acceptable carrier. For oral administration, the carrier may include, but is not limited to, a binder, a lubricant, a disintegrant, an excipient, a solubilizer, a dispersing agent, a stabilizer, a suspending agent, a colorant, and a flavorant. For injectable preparations, the carrier may include a buffering agent, a preserving agent, an analgesic, a solubilizer, an isotonic agent, and a stabilizer. For preparations for topical administration, the carrier may include a base, an excipient, a lubricant, and a preserving agent.
The composition of the present invention may be formulated into a variety of dosage forms in combination with the aforementioned pharmaceutically acceptable carriers. For example, for oral administration, the pharmaceutical composition may be formulated into tablets, troches, capsules, elixirs, suspensions, syrups or wafers. For injectable preparations, the pharmaceutical composition may be formulated into an ampule as a single dosage form or a multidose container. The pharmaceutical composition may also be formulated into solutions, suspensions, tablets, pills, capsules and long-acting preparations.
On the other hand, examples of the carrier, the excipient, and the diluent suitable for the pharmaceutical formulations include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oils. In addition, the pharmaceutical formulations may further include fillers, anti-coagulating agents, lubricants, humectants, flavorants, and antiseptics.
Further, the pharmaceutical composition of the present invention may have any formulation selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquids for internal use, emulsions, syrups, sterile aqueous solutions, non-aqueous solvents, lyophilized formulations and suppositories.
Further, the composition may be formulated into a single dosage form suitable for the patient's body, and preferably is formulated into a preparation useful for peptide drugs according to the typical method in the pharmaceutical field so as to be administered by an oral or parenteral route such as through skin, intravenous, intramuscular, intra-arterial, intramedullary, intramedullary, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, intracolonic, topical, sublingual, vaginal, or rectal administration, but is not limited thereto.
The peptide may be used by blending with a variety of pharmaceutically acceptable carriers such as physiological saline or organic solvents. In order to increase the stability or absorptivity, carbohydrates such as glucose, sucrose or dextrans, antioxidants such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers may be used.
The administration dose and frequency of the pharmaceutical composition of the present invention are determined by the type of active ingredient, together with various factors such as the disease to be treated, administration route, patient's age, gender, and body weight, and disease severity.
The total effective dose of the composition of the present invention may be administered to a patient in a single dose, or may be administered for a long period of time in multiple doses according to a fractionated treatment protocol. In the pharmaceutical composition of the present invention, the content of active ingredient may vary depending on the disease severity. Preferably, the total daily dose of the peptide of the present invention may be approximately 0.0001 ㎍ to 500 mg per 1 kg of body weight of a patient. However, the effective dose of the peptide is determined considering various factors including patient's age, body weight, health conditions, gender, disease severity, diet, and secretion rate, in addition to administration route and treatment frequency of the pharmaceutical composition. In view of this, those skilled in the art may easily determine an effective dose suitable for the particular use of the pharmaceutical composition of the present invention. The pharmaceutical composition according to the present invention is not particularly limited to the formulation, and administration route and mode, as long as it shows the effects of the present invention.
The pharmaceutical composition of the present invention shows excellent in-vivo duration of efficacy and titer, thereby remarkably reducing the number and frequency of administration thereof.
Moreover, the pharmaceutical composition may be administered alone or in combination or coincident with other pharmaceutical formulations showing prophylactic or therapeutic effects on obesity. The pharmaceutical formulations showing prophylactic or therapeutic effects on obesity are not particularly limited, and may include a GLP-1 receptor agonist, a leptin receptor agonist, a DPP-IV inhibitor, a Y5 receptor antagonist, a Melanin-concentrating hormone (MCH) receptor antagonist, a Y2/3 receptor agonist, a MC3/4 receptor agonist, a gastric/pancreatic lipase inhibitor, a 5HT2c agonist, a β3A receptor agonist, an Amylin receptor agonist, a Ghrelin antagonist, and/or a Ghrelin receptor antagonist.
In still another aspect, the present invention provides a method for preventing or treating obesity, comprising the step of administering to a subject the peptide or the pharmaceutical composition including the same.
In the present invention, the term "subject" is those suspected of having obesity, which means mammals including human, mouse, and livestock having obesity or having the possibility of obesity. However, any subject to be treated with the peptide or the pharmaceutical composition of the present invention is included without limitation. The pharmaceutical composition including the peptide of the present invention is administered to a subject suspected of having obesity, thereby treating the subject effectively. The obesity is as described above.
The therapeutic method of the present invention may include the step of administering the composition including the peptide at a pharmaceutically effective amount. The total daily dose should be determined through appropriate medical judgment by a physician, and administered once or several times. With respect to the objects of the present invention, the specific therapeutically effective dose level for any particular patient may vary depending on various factors well known in the medical art, including the kind and degree of the response to be achieved, concrete compositions according to whether other agents are used therewith or not, the patient’s age, body weight, health condition, gender, and diet, the time and route of administration, the secretion rate of the composition, the time period of therapy, other drugs used in combination or coincident with the composition of this invention, and like factors well known in the medical arts.
In still another aspect, the present invention provides a use of the peptide or the pharmaceutical composition including the same in the preparation of drugs for the prevention or treatment of obesity.
Hereinafter, the present invention will be described in more detail with reference to the following Examples. However, these Examples are for illustrative purposes only, and the invention is not intended to be limited by these Examples.
Example 1. Production of in vitro activated cell line
Example 1-1: Production of cell line showing cAMP response to GLP-1
PCR was performed using a region corresponding to ORF (Open Reading Frame) in cDNA (OriGene Technologies, Inc. USA) of human GLP-1 receptor gene as a template, and the following forward and reverse primers including each of the HindIII and EcoRI restriction sites so as to obtain a PCR product.
Forward primer: 5'-CCCGGCCCCCGCGGCCGCTATTCGAAATAC-3'(SEQ ID NO. 47)
Reverse primer: 5'-GAACGGTCCGGAGGACGTCGACTCTTAAGATAG-3'(SEQ ID NO. 48)
The PCR product was cloned into the known animal cell expression vector x0GC/dhfr to prepare a recombinant vector x0GC/GLP1R.
CHO DG44 cell line cultured in DMEM/F12 (10% FBS) medium was transfected with the recombinant vector x0GC/GLP1R using Lipofectamine (Invitrogen, USA), and cultured in a selection medium containing 1 mg/mL G418 and 10 nM methotraxate. Single clone cell lines were selected therefrom by a limit dilution technique, and a cell line showing excellent cAMP response to GLP-1 in a concentration-dependent manner was finally selected therefrom.
Example 1-2: Production of cell line showing cAMP response to glucagon
PCR was performed using a region corresponding to ORF in cDNA (OriGene Technologies, Inc. USA) of human glucagon receptor gene as a template, and the following forward and reverse primers including each of the EcoRI and XhoI restriction sites so as to obtain a PCR product.
Forward primer: 5'-CAGCGACACCGACCGTCCCCCCGTACTTAAGGCC-3'(SEQ ID NO. 49)
Reverse primer: 5'-CTAACCGACTCTCGGGGAAGACTGAGCTCGCC-3'(SEQ ID NO. 50)
The PCR product was cloned into the known animal cell expression vector x0GC/dhfr to prepare a recombinant vector x0GC/GCGR.
CHO DG44 cell line cultured in DMEM/F12 (10% FBS) medium was transfected with the recombinant vector x0GC/GCGR using Lipofectamine, and cultured in a selection medium containing 1 mg/mL G418 and 10 nM methotraxate. Single clone cell lines were selected therefrom by a limit dilution technique, and a cell line showing excellent cAMP response to glucagon in a concentration-dependent manner was finally selected therefrom.
Example 2. Test on in vitro activity of oxyntomodulin derivatives
Example 2-1: Synthesis of oxyntomodulin derivatives
In order to measure in vitro activities of oxyntomodulin derivatives, oxyntomodulin derivatives having the following amino acid sequences were synthesized (Table 1).
Table 1 Oxyntomodulin and oxyntomodulin derivatives
SEQ ID NO . Amino acid sequence
SEQ ID NO. 1 HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA
SEQ ID NO. 2 CA-SQGTFTSDYSKYLDEEAVRLFIEWLMNTKRNRNNIA
SEQ ID NO. 3 CA-SQGTFTSDYSKYLDERRAQDFVAWLKNTGPSSGAPPPS
SEQ ID NO. 4 CA-GQGTFTSDYSRYLEEEAVRLFIEWLKNGGPSSGAPPPS
SEQ ID NO. 5 CA-GQGTFTSDYSRQMEEEAVRLFIEWLKNGGPSSGAPPPS
SEQ ID NO. 6 CA-GEGTFTSDLSRQMEEEAVRLFIEWAAHSQGTFTSDYSKYLD
SEQ ID NO. 7 CA-SQGTFTSDYSRYLDEEAVRLFIEWLMNTK
SEQ ID NO. 8 CA-SQGTFTSDLSRQLEEEAVRLFIEWLMNK
SEQ ID NO. 9 CA-GQGTFTSDYSRYLDEEAVXLFIEWLMNTKRNRNNIA
SEQ ID NO. 10 CA-SQGTFTSDYSRQMEEEAVRLFIEWLMNGGPSSGAPPPSK
SEQ ID NO. 11 CA-GEGTFTSDLSRQMEEEAVRLFIEWAAHSQGTFTSDYSRYLDK
SEQ ID NO. 12 CA-SQGTFTSDYSRYLDGGGHGEGTFTSDLSKQMEEEAVK
SEQ ID NO. 13 CA-SQGTFTSDYSRYLDXEAVXLFIEWLMNTK
SEQ ID NO. 14 CA-GQGTFTSDYSRYLDEEAVXLFIXWLMNTKRNRNNIA
SEQ ID NO. 15 CA-GQGTFTSDYSRYLDEEAVRLFIXWLMNTKRNRNNIA
SEQ ID NO. 16 CA-SQGTFTSDLSRQLEGGGHSQGTFTSDLSRQLEK
SEQ ID NO. 17 CA-SQGTFTSDYSRYLDEEAVRLFIEWIRNTKRNRNNIA
SEQ ID NO. 18 CA-SQGTFTSDYSRYLDEEAVRLFIEWIRNGGPSSGAPPPSK
SEQ ID NO. 19 CA-SQGTFTSDYSRYLD E EAV K LFIEWIRNTKRNRNNIA
SEQ ID NO. 20 CA-SQGTFTSDYSRYLD E EAV K LFIEWIRNGGPSSGAPPPSK
SEQ ID NO. 21 CA-SQGTFTSDYSRQLEEEAVRLFIEWVRNTKRNRNNIA
SEQ ID NO. 22 DA-SQGTFTSDYSKYLD E KRA K EFVQWLMNTK
SEQ ID NO. 23 HAibQGTFTSDYSKYLDEKRAKEFVCWLMNT
SEQ ID NO. 24 HAibQGTFTSDYSKYLDEKRAKEFVQWLMNTC
SEQ ID NO. 25 HAibQGTFTSDYSKYLD E KRA K EFVQWLMNTC
SEQ ID NO. 26 HAibQGTFTSDYS K YLD E KRAKEFVQWLMNTC
SEQ ID NO. 27 HAibQGTFTSDYSKYLD E QAA K EFICWLMNT
SEQ ID NO. 28 HAibQGTFTSDYSKYLDEKRAKEFVQWLMNT
SEQ ID NO. 29 CA-AibQGTFTSDYSKYLD E KRA K EFVQWLMNTC
SEQ ID NO. 30 HAibQGTFTSDYAKYLD E KRA K EFVQWLMNTC
SEQ ID NO. 31 YAibQGTFTSDYSKYLD E KRA K EFVQWLMNTC
In Table 1, amino acids in bold and underlined represent ring formation, and amino acids represented by X mean a non-native amino acid, alpha-methyl-glutamic acid. In addition, CA represents 4-imidazoacetyl, and DA represents desamino-histidyl.
Example 2-2: Test on in vitro activity of oxyntomodulin derivatives
In order to measure anti-obesity efficacies of the oxyntomodulin derivatives synthesized in Example 2-1, cell activity was measured in vitro using the cell lines prepared in Examples 1-1 and 1-2.
The cell lines were those prepared by transfecting CHO (Chinese Hamster Ovary) to express human GLP-1 receptor gene and glucagon receptor gene, respectively. Thus, they are suitable to measure GLP-1 and glucagon activities. Therefore, the activity of each oxyntomodulin derivative was measured using each transformed cell line.
Specifically, each cell line was sub-cultured twice or three time a week, and aliquoted in each well of a 96-well plate at a density of 1 X 105, followed by cultivation for 24 hours.
The cultured cells were washed with KRB buffer and suspended in 40 ml of KRB buffer containing 1 mM IBMX, and left at room temperature for 5 minutes. Oxyntomodulin (SEQ ID NO. 1) and oxyntomodulin derivatives (represented by SEQ ID NOs. 2-6, 8, 10-13, 17, 18, 23-25, 27-30 and 31) were diluted from 1000 nM to 0.02 nM by 5-fold serial dilution, and each 40 mL thereof was added to the cells, and cultured at 37°C for 1 hour in a CO2 incubator. Then, 20 mL of cell lysis buffer was added for cell lysis, and the cell lysates were applied to a cAMP assay kit (Molecular Device, USA) to measure cAMP concentrations. EC50 values were calculated therefrom, and compared to each other. EC50 values are shown in the following Table 2.
Table 2 Comparison of in vitro activities for GLP-1 receptor and glucagon receptor between oxyntomodulin and oxyntomodulin derivatives
SEQ ID NO. EC50(nM)
CHO/GLP-1R CHO/GCGR
SEQ ID NO. 1 50 - 210 10 - 43
SEQ ID NO. 2 51.8 12.8
SEQ ID NO. 3 >1,000 637.7
SEQ ID NO. 4 5.5 >1,000
SEQ ID NO. 5 5.9 >1,000
SEQ ID NO. 6 500.1 >1,000
SEQ ID NO. 8 419.6 >1,000
SEQ ID NO. 10 >1,000 >1,000
SEQ ID NO. 11 >1,000 >1,000
SEQ ID NO. 12 >1,000 >1,000
SEQ ID NO. 13 >1,000 >1,000
SEQ ID NO. 17 97.9 >1,000
SEQ ID NO. 18 96.3 >1,000
SEQ ID NO. 23 2.46 5.8
SEQ ID NO. 24 1.43 6.95
SEQ ID NO. 25 1.9 1.3
SEQ ID NO. 27 2.8-5.5 3.1-5.6
SEQ ID NO. 28 3.1 0.3
SEQ ID NO. 29 14.25 17.3
SEQ ID NO. 30 2.20 80.2
SEQ ID NO. 31 12.5 1.0
As shown in Table 2, there were oxyntomodulin derivatives showing excellent in vitro activities and different ratios of activities on GLP-1 receptor and glucagon receptor, compared to native oxyntomodulin of SEQ ID NO. 1.
It is known that oxyntomodulin activates both the GLP-1 receptor and glucagon receptor to suppress appetite, facilitate lipolysis, and promote satiety, thereby showing anti-obesity effects. The oxyntomodulin derivatives according to the present invention show higher in vitro activities on both the GLP-1 receptor and glucagon receptor than the wild-type oxyntomodulin, and therefore can be used as a therapeutic agent for obesity with higher efficacies than the known oxyntomodulin.
Example 3. Test on in vivo activity of oxyntomodulin derivatives
In order to measure in vivo therapeutic activity of oxyntomodulin derivatives, changes in food intake by administration of oxyntomodulin derivatives were examined in ob/ob mouse using native oxyntomodulin as a control.
Specifically, obese diabetic ob/ob mice, commonly used to test the efficacies of therapeutic agents for obesity and diabetes, were fasted for 16 hours, and administered with 1 or 10 mg/kg of oxyntomodulin, or 0.02, 0.1, 1 or 10 mg/kg of the oxyntomodulin derivative of SEQ ID NO. 2. Then, food intake was examined for 2 hours (FIG. 1). FIG. 1 is a graph showing changes in food intake according to administration dose of oxyntomodulin or oxyntomodulin derivative. As shown in FIG. 1, administration of 1 mg/kg of oxyntomodulin derivative showed more excellent inhibitory effects on food intake than administration of 10 mg/kg of oxyntomodulin.
Taken together, the oxyntomodulin derivatives of the present invention have much higher anti-obesity effects than the wild-type oxyntomodulin, even though administered at a lower dose, indicating improvement in the problems of the wild-type oxyntomodulin that shows lower anti-obesity effects and should be administered at a high dose three times a day.

Claims (14)

  1. A peptide comprising the amino acid sequence of following Formula 1:
    R1-X1-X2-GTFTSD-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-X22-X23-X24-R2 (Formula 1)
    wherein R1 is histidine, desamino-histidyl, dimethyl-histidyl (N-dimethyl-histidyl), beta-hydroxyimidazopropionyl, 4-imidazoacetyl, beta-carboxy imidazopropionyl or tyrosine;
    X1 is Aib(aminoisobutyric acid), d-alanine, glycine, Sar(N-methylglycine), serine, or d-serine;
    X2 is glutamic acid or glutamine;
    X3 is leucine or tyrosine;
    X4 is serine or alanine;
    X5 is lysine or arginine;
    X6 is glutamine or tyrosine;
    X7 is leucine or methionine;
    X8 is aspartic acid or glutamic acid;
    X9 is glutamic acid, serine, alpha-methyl-glutamic acid or is deleted;
    X10 is glutamine, glutamic acid, lysine, arginine, serine or is deleted;
    X11 is alanine, arginine, valine or is deleted;
    X12 is alanine, arginine, serine, valine or is deleted;
    X13 is lysine, glutamine, arginine, alpha-methyl-glutamic acid or is deleted;
    X14 is aspartic acid, glutamic acid, leucine or is deleted;
    X15 is phenylalanine or is deleted;
    X16 is isoleucine, valine or is deleted;
    X17 is alanine, cysteine, glutamic acid, lysine, glutamine, alpha-methyl-glutamic acid or is deleted;
    X18 is tryptophan or is deleted;
    X19 is alanine, isoleucine, leucine, serine, valine or is deleted;
    X20 is alanine, lysine, methionine, glutamine, arginine or is deleted;
    X21 is asparagine or is deleted;
    X22 is alanine, glycine, threonine or is deleted;
    X23 is cysteine, lysine or is deleted;
    X24 is a peptide having 2 to 10 amino acids consisting of combinations of alanine, glycine and serine, or is deleted; and
    R2 is KRNRNNIA (SEQ ID NO. 32), GPSSGAPPPS (SEQ ID NO. 33), GPSSGAPPPSK (SEQ ID NO. 34), HSQGTFTSDYSKYLD (SEQ ID NO. 35), HSQGTFTSDYSRYLDK (SEQ ID NO. 36), HGEGTFTSDLSKQMEEEAVK (SEQ ID NO. 37) or is deleted (excluded if the amino acid sequence of Formula 1 is identical to that of SEQ ID NO. 1).
  2. The peptide according to claim 1, wherein the peptide is an oxyntomodulin derivative capable of activating GLP-1 receptor and glucagon receptor.
  3. The peptide according to claim 1, wherein the peptide has anti-obesity effects.
  4. The peptide according to claim 1, wherein one or more amino acids at positions 10, 14, 16, 20, 24 and 28 of the amino acid sequence of Formula 1 are substituted with amino acids or amino acid derivatives selected from the group consisting of Tyr(4-Me), Phe, Phe(4-Me), Phe(4-Cl), Phe(4-CN), Phe(4-NO2), Phe(4-NH2), Phg, Pal, Nal, Ala(2-thienyl) and Ala(benzothienyl).
  5. The peptide according to claim 1, wherein one or more amino acid pairs at positions 10 and 14, 12 and 16, 16 and 20, 20 and 24, and 24 and 28 of the amino acid sequence of Formula 1 are substituted with glutamic acid or lysine to form rings.
  6. The peptide according to claim 1, wherein one or more amino acid pairs at positions 10 and 14, 12 and 16, 16 and 20, 20 and 24, and 24 and 28 of the amino acid sequence of Formula 1 form rings.
  7. The peptide according to claim 1, wherein the peptide is selected from the group consisting of the peptides of SEQ ID NOs. 1 to 31.
  8. A polynucleotide encoding the peptide of claim 1.
  9. A pharmaceutical composition for the prevention or treatment of obesity, comprising the peptide of any one of claims 1 to 7 as an active ingredient.
  10. The pharmaceutical composition according to claim 9, further comprising a pharmaceutically acceptable carrier.
  11. The pharmaceutical composition according to claim 9, wherein the composition is administered alone or in combination or coincident with other pharmaceutical formulations showing prophylactic or therapeutic effects on obesity.
  12. The pharmaceutical composition according to claim 11, wherein the pharmaceutical formulation showing prophylactic or therapeutic effects on obesity is selected from the group consisting of a GLP-1 receptor agonist, a leptin receptor agonist, a DPP-IV inhibitor, a Y5 receptor antagonist, a Melanin-concentrating hormone (MCH) receptor antagonist, a Y2/3 receptor agonist, a MC3/4 receptor agonist, a gastric/pancreatic lipase inhibitor, a 5HT2c agonist, a β3A receptor agonist, an Amylin receptor agonist, a Ghrelin antagonist, and a Ghrelin receptor antagonist.
  13. A method for preventing or treating obesity, comprising the step of administering to a subject the peptide of any one of claims 1 to 7 or the composition of claim 9.
  14. Use of the peptide of any one of claims 1 to 7 or the composition of claim 9 in the preparation of drugs for the prevention or treatment of obesity.
PCT/KR2012/004494 2011-06-10 2012-06-07 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same WO2012169798A2 (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
SI201231406T SI2718318T1 (en) 2011-06-10 2012-06-07 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
RS20181080A RS57711B1 (en) 2011-06-10 2012-06-07 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
CN201280038851.4A CN103732618B (en) 2011-06-10 2012-06-07 It is novel to secrete the sour pharmaceutical composition for treating obesity for adjusting peptide derivant and acid adjusting peptide derivant is secreted comprising this
ES12797363.4T ES2692187T3 (en) 2011-06-10 2012-06-07 New oxintomodulin derivatives and pharmaceutical composition for the treatment of obesity comprising it
MX2013014468A MX350708B (en) 2011-06-10 2012-06-07 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same.
EP12797363.4A EP2718318B1 (en) 2011-06-10 2012-06-07 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
BR122020011001-5A BR122020011001B1 (en) 2011-06-10 2012-06-07 OXINTOMODULIN DERIVATIVES PEPTIDE AND THEIR USE, POLYNUCLEOTIDE, PHARMACEUTICAL COMPOSITION AND THEIR USE AND METHOD FOR THE PREVENTION OR TREATMENT OF OBESITY INCLUDING THE SAME
CA2838503A CA2838503C (en) 2011-06-10 2012-06-07 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
PL12797363T PL2718318T3 (en) 2011-06-10 2012-06-07 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
NZ618810A NZ618810B2 (en) 2011-06-10 2012-06-07 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
PE2023001927A PE20240686A1 (en) 2011-06-10 2012-06-07 PEPTIDES DERIVED FROM OXYNTOMODULIN WITH ACTIVITY ON THE GLUCAGON RECEPTOR AND THE GLUCAGON-LIKE PEPTIDE RECEPTOR TYPE 1 (GLP-1)
EP18177993.5A EP3434687B1 (en) 2011-06-10 2012-06-07 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
DK12797363.4T DK2718318T3 (en) 2011-06-10 2012-06-07 New oxyntomodulin derivatives and pharmaceutical compositions for the treatment of obesity comprising these
AU2012267398A AU2012267398B2 (en) 2011-06-10 2012-06-07 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
EP21161174.4A EP3878859B1 (en) 2011-06-10 2012-06-07 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
RU2013154066A RU2612906C2 (en) 2011-06-10 2012-06-07 New derivatives of oxyntomodulin and pharmaceutical composition for treating obesity
US14/124,969 US9527898B2 (en) 2011-06-10 2012-06-07 Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
LTEP12797363.4T LT2718318T (en) 2011-06-10 2012-06-07 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
SG2013089065A SG195258A1 (en) 2011-06-10 2012-06-07 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
JP2014514799A JP6014127B2 (en) 2011-06-10 2012-06-07 Novel oxyntomodulin derivative and composition for treating obesity comprising the same
BR112013031794-9A BR112013031794B1 (en) 2011-06-10 2012-06-07 peptides derived from oxintomodulin and their use, polynucleotide, pharmaceutical composition and their use and method for the prevention or treatment of obesity comprising the same
UAA201314212A UA114710C2 (en) 2011-06-10 2012-06-07 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
ZA2013/09054A ZA201309054B (en) 2011-06-10 2013-12-03 Novel Oxyntomodulin Derivatives and Pharmaceutical Composition for Treating Obesity Comprising the Same
US14/748,389 US9522946B2 (en) 2011-06-10 2015-06-24 Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
IL245557A IL245557B (en) 2011-06-10 2016-05-09 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
US15/286,708 US9765131B2 (en) 2011-06-10 2016-10-06 Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
AU2016273908A AU2016273908B2 (en) 2011-06-10 2016-12-14 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
US15/675,274 US10442848B2 (en) 2011-06-10 2017-08-11 Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
IL260582A IL260582B (en) 2011-06-10 2018-07-12 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
AU2018213964A AU2018213964B2 (en) 2011-06-10 2018-08-06 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
HRP20181591TT HRP20181591T1 (en) 2011-06-10 2018-10-03 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
CY181101088T CY1120781T1 (en) 2011-06-10 2018-10-23 INNOVATIVE OXYNTOMODULIN PRODUCTS AND PHARMACEUTICAL COMPOSITION FOR TREATMENT THAT CONTAINS THEM
IL268984A IL268984B (en) 2011-06-10 2019-08-28 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
AU2020201322A AU2020201322B2 (en) 2011-06-10 2020-02-24 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0056472 2011-06-10
KR20110056472 2011-06-10

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US14/124,969 A-371-Of-International US9527898B2 (en) 2011-06-10 2012-06-07 Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
US14/748,389 Division US9522946B2 (en) 2011-06-10 2015-06-24 Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
US15/286,708 Continuation US9765131B2 (en) 2011-06-10 2016-10-06 Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same

Publications (2)

Publication Number Publication Date
WO2012169798A2 true WO2012169798A2 (en) 2012-12-13
WO2012169798A3 WO2012169798A3 (en) 2013-02-14

Family

ID=47296599

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/004494 WO2012169798A2 (en) 2011-06-10 2012-06-07 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same

Country Status (30)

Country Link
US (4) US9527898B2 (en)
EP (3) EP3878859B1 (en)
JP (5) JP6014127B2 (en)
KR (2) KR101502299B1 (en)
CN (1) CN103732618B (en)
AR (1) AR086866A1 (en)
AU (4) AU2012267398B2 (en)
BR (2) BR122020011001B1 (en)
CA (2) CA3064214C (en)
CL (1) CL2013003547A1 (en)
CY (1) CY1120781T1 (en)
DK (3) DK3878859T5 (en)
ES (3) ES2968043T3 (en)
HR (1) HRP20181591T1 (en)
HU (1) HUE040307T2 (en)
IL (3) IL245557B (en)
LT (1) LT2718318T (en)
MX (2) MX350708B (en)
MY (1) MY169309A (en)
PE (3) PE20140765A1 (en)
PL (1) PL2718318T3 (en)
PT (1) PT2718318T (en)
RS (1) RS57711B1 (en)
RU (2) RU2612906C2 (en)
SG (2) SG10201604564XA (en)
SI (1) SI2718318T1 (en)
TW (2) TWI674271B (en)
UA (2) UA126465C2 (en)
WO (1) WO2012169798A2 (en)
ZA (1) ZA201309054B (en)

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
US20140212440A1 (en) * 2011-06-17 2014-07-31 Hanmi Science Co., Ltd Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
WO2014170496A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
JP2015524427A (en) * 2012-07-25 2015-08-24 ハンミ ファーマシューティカル カンパニー リミテッド Compositions for the treatment of hyperlipidemia comprising oxyntomodulin derivatives
WO2015183054A1 (en) 2014-05-30 2015-12-03 Hanmi Pharm. Co., Ltd. Composition for treating diabetes mellitus comprising insulin and a glp-1/glucagon dual agonist
WO2015185640A1 (en) 2014-06-04 2015-12-10 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
WO2015186988A1 (en) 2014-06-05 2015-12-10 Hanmi Pharm. Co., Ltd. Method for decreasing immunogenicity of protein and peptide
US9365632B2 (en) 2012-10-09 2016-06-14 Sanofi Exendin-4 derivatives as dual GLP1/glucagon agonists
WO2016108617A1 (en) * 2014-12-30 2016-07-07 Hanmi Pharm. Co., Ltd. Glucagon derivatives
US9486505B2 (en) 2011-09-23 2016-11-08 Novo Nordisk A/S Glucagon analogues
US9522946B2 (en) 2011-06-10 2016-12-20 Hanmi Science Co., Ltd. Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
WO2017003191A1 (en) 2015-06-30 2017-01-05 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
US9670261B2 (en) 2012-12-21 2017-06-06 Sanofi Functionalized exendin-4 derivatives
US9694053B2 (en) 2013-12-13 2017-07-04 Sanofi Dual GLP-1/glucagon receptor agonists
US9724420B2 (en) 2012-11-06 2017-08-08 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin FC region
US9750788B2 (en) 2013-12-13 2017-09-05 Sanofi Non-acylated exendin-4 peptide analogues
US9751926B2 (en) 2013-12-13 2017-09-05 Sanofi Dual GLP-1/GIP receptor agonists
US9758561B2 (en) 2014-04-07 2017-09-12 Sanofi Dual GLP-1/glucagon receptor agonists derived from exendin-4
US9771406B2 (en) 2014-04-07 2017-09-26 Sanofi Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4
US9775904B2 (en) 2014-04-07 2017-10-03 Sanofi Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9789165B2 (en) 2013-12-13 2017-10-17 Sanofi Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
EP3248611A1 (en) * 2010-07-21 2017-11-29 Hanmi Science Co., Ltd. Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
KR20180002544A (en) * 2016-06-29 2018-01-08 한미약품 주식회사 glucagon derivative, a conjugate thereof, and a composition comprising the same, and a therapeutic use thereof
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9982029B2 (en) 2015-07-10 2018-05-29 Sanofi Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
US10017557B2 (en) 2015-08-28 2018-07-10 Hanmi Pharm. Co., Ltd. Insulin analogs and use thereof
WO2018143729A1 (en) 2017-02-03 2018-08-09 한미약품 주식회사 Conjugate of bioactive material having enhanced sustainability and use thereof
EP3241841A4 (en) * 2014-12-30 2018-10-17 Hanmi Pharm. Co., Ltd. Glucagon derivative having improved stability
US10159715B2 (en) 2014-05-29 2018-12-25 Hanmi Pharm. Co., Ltd Method for treating diabetes comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate
US10233230B2 (en) 2014-09-16 2019-03-19 Hanmi Pharm. Co., Ltd. Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
US10253082B2 (en) 2014-01-20 2019-04-09 Hanmi Pharm. Co., Ltd Long-acting insulin and use thereof
KR101990075B1 (en) * 2018-07-19 2019-06-18 ㈜ 디앤디파마텍 Pharmaceutical composition for preventing or treating obesity comprising a polypeptide
US10370426B2 (en) 2015-12-31 2019-08-06 Hanmi Pharm. Co., Ltd Triple glucagon/GLP-1/GIP receptor agonist
WO2020017916A1 (en) 2018-07-19 2020-01-23 D&D Pharmatech Inc. Pharmaceutical composition comprising polypeptide
US10550168B2 (en) 2012-11-06 2020-02-04 Hanmi Pharm. Co., Ltd. Composition for treating diabetes or diabesity comprising oxyntomodulin analog
US10806797B2 (en) 2015-06-05 2020-10-20 Sanofi Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate
EP3889185A2 (en) 2014-03-31 2021-10-06 Hanmi Pharm. Co., Ltd. Composition for improving the solubility of a protein or peptide by using immunoglobulin fc fragment linkage
US11168109B2 (en) 2012-03-08 2021-11-09 Hanmi Science Co., Ltd. Process for preparation of physiologically active polypeptide complex
US11396534B2 (en) 2016-09-23 2022-07-26 Hanmi Pharm. Co., Ltd. Insulin analogs with reduced affinity to insulin receptor and use thereof
US11434271B2 (en) 2011-11-04 2022-09-06 Hanmi Science Co., Ltd. Method for preparing physiologically active polypeptide complex
US11752216B2 (en) 2017-03-23 2023-09-12 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof
EP4148064A4 (en) * 2020-05-09 2024-06-12 Tianjin Institute Of Pharmaceutical Research Co., Ltd. Polypeptide derivative having dual receptor agonistic action and use thereof

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR096890A1 (en) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd CONJUGATING FC OF IMMUNOGLOBULINA, THAT MAINTAINS THE UNION AFFINITY OF THE FC FRAGMENT OF THE IMMUNOGLOBULIN TO FCRN
AR096891A1 (en) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd CONJUGATE OF BIOMOLOGICALLY ACTIVE POLYPEPTIDE MONOMER AND CONJUGATE OF FRAGMENTO FC OF IMMUNOGLOBULINA, THAT SHOWS CLEARING THROUGH REDUCED RECEPTOR, AND THE METHOD FOR PREPARING THE SAME
AR098614A1 (en) * 2013-12-18 2016-06-01 Lilly Co Eli COMPOUND FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA
AR098615A1 (en) * 2013-12-18 2016-06-01 Lilly Co Eli PEPTIDE FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA
AU2017268161B2 (en) * 2016-05-16 2020-03-12 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
CN110291103A (en) 2016-12-05 2019-09-27 韩美药品株式会社 The conjugate of immune response with reduction
CN108299554B (en) * 2017-01-13 2021-05-25 博瑞生物医药（苏州）股份有限公司 Oxyntomodulin analogues
CN106986924A (en) * 2017-03-23 2017-07-28 中国药科大学 Oxyntomodulin（OXM）Analog and its application
US11970523B2 (en) * 2018-07-25 2024-04-30 China Pharmaceutical University Long-acting oxyntomodulin hybrid peptide, preparation method therefor, and application thereof
WO2020071865A1 (en) * 2018-10-04 2020-04-09 한미약품 주식회사 Therapeutic uses of glucagon and combined product comprising same
US20200262887A1 (en) 2018-11-30 2020-08-20 Opko Ireland Global Holdings, Ltd. Oxyntomodulin peptide analog formulations
WO2024080824A1 (en) * 2022-10-14 2024-04-18 한미약품 주식회사 Novel glp-1 receptor antagonist, and pharmaceutical composition for preventing or treating congenital hyperinsulinemia or hypoglycemia, comprising same

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
AU749815B2 (en) 1998-03-06 2002-07-04 Chugai Seiyaku Kabushiki Kaisha Protein-free preparations
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7217845B2 (en) 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1594530A4 (en) * 2003-01-22 2006-10-11 Human Genome Sciences Inc Albumin fusion proteins
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
DK2256134T3 (en) 2003-11-13 2014-02-24 Hanmi Science Co Ltd IgG Fc fragment to a drug carrier and process for preparation thereof
KR101135244B1 (en) 2007-11-29 2012-04-24 한미사이언스 주식회사 A pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
US20090238838A1 (en) 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
EP2769990A3 (en) 2004-12-02 2015-02-25 Domantis Limited Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
KR20070115947A (en) * 2005-02-11 2007-12-06 아밀린 파마슈티칼스, 인크. Gip analog and hybrid polypeptides with selectable properties
KR100754667B1 (en) 2005-04-08 2007-09-03 한미약품 주식회사 Immunoglobulin Fc fragment modified by non-peptide polymer and pharmaceutical composition comprising the same
AU2006258841B2 (en) 2005-06-13 2012-05-03 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
US7928058B2 (en) 2006-02-22 2011-04-19 Merck Sharp & Dohme Corp. Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
WO2007146038A2 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
GB0624868D0 (en) 2006-12-13 2007-01-24 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP2008169195A (en) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd Insulinotopic peptide drug combo using carrier material
KR20150116465A (en) 2007-02-15 2015-10-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon/glp-1 receptor co-agonists
ATE499088T1 (en) 2007-07-10 2011-03-15 Lilly Co Eli GLP-1-FC FUSION PROTEIN FORMULATION
WO2009046859A2 (en) 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of af12198 and dago as therapeutic agents
US8980830B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
AU2009210570B2 (en) 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
KR20110039230A (en) 2008-06-17 2011-04-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
JP5775450B2 (en) * 2008-06-17 2015-09-09 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon / GLP-1 receptor co-agonist
WO2010013012A2 (en) 2008-08-01 2010-02-04 Lund University Bioscience Ab Novel polypeptides and uses thereof
US20110171312A1 (en) 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use
EP2341942A1 (en) 2008-09-19 2011-07-13 Nektar Therapeutics Polymer conjugates of therapeutic peptides
ES2439499T3 (en) 2008-12-15 2014-01-23 Zealand Pharma A/S Glucagon analogues
TWI489992B (en) 2008-12-19 2015-07-01 印地安那大學研究及技術公司 Amide based glucagon superfamily peptide prodrugs
WO2010096052A1 (en) * 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
JP2012521197A (en) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Carrier immunoglobulin and use thereof
SG174320A1 (en) 2009-03-20 2011-10-28 Hanmi Holdings Co Ltd Method for preparing a site-specific physiologically active polypeptide conjugate
IN2012DN00377A (en) 2009-06-16 2015-08-21 Univ Indiana Res & Tech Corp
NZ597981A (en) 2009-07-13 2014-02-28 Zealand Pharma As Acylated glucagon analogues
WO2011056713A2 (en) 2009-11-03 2011-05-12 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for obstructive sleep apnea
WO2011071957A1 (en) 2009-12-07 2011-06-16 Sea Lane Biotechnologies, Llc Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
AR079345A1 (en) 2009-12-22 2012-01-18 Lilly Co Eli OXINTOMODULINE PEPTIDAL ANALOG
AR079344A1 (en) 2009-12-22 2012-01-18 Lilly Co Eli PEPTIDAL ANALOG OF OXINTOMODULIN, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT NON-INSULINED INDEPENDENT DIABETES AND / OR OBESITY
CA2792663A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
CN103179976A (en) 2010-05-13 2013-06-26 印第安纳大学研究及科技有限公司 Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
CN103179979A (en) 2010-06-24 2013-06-26 印第安纳大学研究及科技有限公司 Amide based glucagon superfamily peptide prodrugs
KR101382593B1 (en) 2010-07-21 2014-04-10 한미사이언스 주식회사 Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
CN101974077A (en) 2010-09-15 2011-02-16 南京瑞年天平医药科技有限公司 Novel polypeptide compound
KR101767570B1 (en) 2010-10-26 2017-08-14 한미사이언스 주식회사 A long-lasting conjugate of An anti-obesity peptide derivative complex
KR101303388B1 (en) 2010-10-26 2013-09-03 한미사이언스 주식회사 Liquid formulations of long acting interferon alpha conjugate
CN102010473A (en) 2010-11-10 2011-04-13 曹鹏 Recombinant oxyntomodulin (OXM) fusion protein, and preparation and application thereof
KR20140020851A (en) 2010-12-22 2014-02-19 마르카디아 바이오테크, 인코퍼레이트 Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
EP2492749A1 (en) 2011-02-28 2012-08-29 Rohm and Haas Electronic Materials LLC Photoresist compositions and methods of forming photolithographic patterns
KR101161526B1 (en) 2011-05-16 2012-07-02 숭실대학교산학협력단 Catalyst electrode of core/shell nanostructure supports and method of it for fuel cell
KR101502299B1 (en) 2011-06-10 2015-03-11 한미사이언스 주식회사 Novel oxyntomodulin derivatives and Pharmaceutical Composition for treating obesity comprising the same
MY164680A (en) 2011-06-17 2018-01-30 Hanmi Science Co Ltd A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
KR20140043793A (en) 2011-06-22 2014-04-10 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon/glp-1 receptor co-agonists
EP2838552A4 (en) 2012-04-19 2016-05-18 Opko Biolog Ltd Long-acting oxyntomodulin variants and methods of producing same
CN104583232B (en) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 Show the glucagon analogs of GIP receptor actives
KR101968344B1 (en) 2012-07-25 2019-04-12 한미약품 주식회사 A composition for treating hyperlipidemia comprising oxyntomodulin analog
AR092873A1 (en) 2012-09-26 2015-05-06 Cadila Healthcare Ltd PEPTIDES AS TRIPLE AGONISTS OF GIP, GLP-1 AND GLUGAGON RECEPTORS
AU2013342321B2 (en) 2012-11-06 2017-09-28 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (en) 2012-11-06 2019-10-01 한미약품 주식회사 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
JP6137046B2 (en) 2014-05-09 2017-05-31 信越化学工業株式会社 Monomer, polymer compound, resist material and pattern forming method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None

Cited By (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3248611A1 (en) * 2010-07-21 2017-11-29 Hanmi Science Co., Ltd. Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
US9527898B2 (en) 2011-06-10 2016-12-27 Hanmi Science Co., Ltd. Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
US10442848B2 (en) 2011-06-10 2019-10-15 Hanmi Science Co., Ltd. Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
US9765131B2 (en) 2011-06-10 2017-09-19 Hanmi Science Co., Ltd. Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
US9522946B2 (en) 2011-06-10 2016-12-20 Hanmi Science Co., Ltd. Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
US11872283B2 (en) 2011-06-17 2024-01-16 Hanmi Science Co., Ltd Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
AU2017202672B2 (en) * 2011-06-17 2019-01-17 Hanmi Science Co., Ltd. A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
US9731031B2 (en) * 2011-06-17 2017-08-15 Hanmi Science Co., Ltd. Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
AU2018282298B2 (en) * 2011-06-17 2020-06-18 Hanmi Science Co., Ltd. A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
US20170340753A1 (en) * 2011-06-17 2017-11-30 Hanmi Science Co., Ltd Conjugate Comprising Oxyntomodulin And An Immunoglobulin Fragment, And Use Thereof
US10363320B2 (en) 2011-06-17 2019-07-30 Hanmi Science Co., Ltd. Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
US20140212440A1 (en) * 2011-06-17 2014-07-31 Hanmi Science Co., Ltd Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
US9486505B2 (en) 2011-09-23 2016-11-08 Novo Nordisk A/S Glucagon analogues
US9486506B2 (en) 2011-09-23 2016-11-08 Novo Nordisk A/S Glucagon analogues
US11434271B2 (en) 2011-11-04 2022-09-06 Hanmi Science Co., Ltd. Method for preparing physiologically active polypeptide complex
US11168109B2 (en) 2012-03-08 2021-11-09 Hanmi Science Co., Ltd. Process for preparation of physiologically active polypeptide complex
US10493132B2 (en) 2012-07-25 2019-12-03 Hanmi Pharm. Co., Ltd. Composition for treating hyperlipidemia comprising oxyntomodulin derivative
US9901621B2 (en) 2012-07-25 2018-02-27 Hanmi Pharm. Co., Ltd. Composition for treating hyperlipidemia comprising oxyntomodulin derivative
EP3384925A1 (en) * 2012-07-25 2018-10-10 Hanmi Pharm. Co., Ltd. Composition for treating hyperlipidemia comprising oxyntomodulin derivative
JP2015524427A (en) * 2012-07-25 2015-08-24 ハンミ ファーマシューティカル カンパニー リミテッド Compositions for the treatment of hyperlipidemia comprising oxyntomodulin derivatives
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
US9365632B2 (en) 2012-10-09 2016-06-14 Sanofi Exendin-4 derivatives as dual GLP1/glucagon agonists
US10758592B2 (en) 2012-10-09 2020-09-01 Sanofi Exendin-4 derivatives as dual GLP1/glucagon agonists
US11071785B2 (en) 2012-11-06 2021-07-27 Hanmi Pharm. Co., Ltd. Liquid formulation of long-lasting protein conjugate comprising the oxyntomodulin and an immunoglobulin Fc region
US10279041B2 (en) 2012-11-06 2019-05-07 Hanmi Pharm Co. Ltd. Liquid formulation of long-lasting protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
US10550168B2 (en) 2012-11-06 2020-02-04 Hanmi Pharm. Co., Ltd. Composition for treating diabetes or diabesity comprising oxyntomodulin analog
US9724420B2 (en) 2012-11-06 2017-08-08 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin FC region
US10253079B2 (en) 2012-12-21 2019-04-09 Sanofi Functionalized Exendin-4 derivatives
US9745360B2 (en) 2012-12-21 2017-08-29 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists
US9670261B2 (en) 2012-12-21 2017-06-06 Sanofi Functionalized exendin-4 derivatives
WO2014170496A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US9751927B2 (en) 2013-04-18 2017-09-05 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
US9474790B2 (en) 2013-04-18 2016-10-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
US9789165B2 (en) 2013-12-13 2017-10-17 Sanofi Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
US9750788B2 (en) 2013-12-13 2017-09-05 Sanofi Non-acylated exendin-4 peptide analogues
US9694053B2 (en) 2013-12-13 2017-07-04 Sanofi Dual GLP-1/glucagon receptor agonists
US9751926B2 (en) 2013-12-13 2017-09-05 Sanofi Dual GLP-1/GIP receptor agonists
US10253082B2 (en) 2014-01-20 2019-04-09 Hanmi Pharm. Co., Ltd Long-acting insulin and use thereof
EP3889185A2 (en) 2014-03-31 2021-10-06 Hanmi Pharm. Co., Ltd. Composition for improving the solubility of a protein or peptide by using immunoglobulin fc fragment linkage
US9758561B2 (en) 2014-04-07 2017-09-12 Sanofi Dual GLP-1/glucagon receptor agonists derived from exendin-4
US9771406B2 (en) 2014-04-07 2017-09-26 Sanofi Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4
US9775904B2 (en) 2014-04-07 2017-10-03 Sanofi Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US10159715B2 (en) 2014-05-29 2018-12-25 Hanmi Pharm. Co., Ltd Method for treating diabetes comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate
TWI684458B (en) * 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 Composition for treating diabetes mellitus comprising insulin and a glp-1/glucagon dual agonist
US10188703B2 (en) 2014-05-30 2019-01-29 Hanmi Pharm. Co., Ltd. Method for treating diabetes mellitus by a composition comprising insulin and a GLP-1/glucagon dual agonist
WO2015183054A1 (en) 2014-05-30 2015-12-03 Hanmi Pharm. Co., Ltd. Composition for treating diabetes mellitus comprising insulin and a glp-1/glucagon dual agonist
AU2015268199B2 (en) * 2014-05-30 2020-12-10 Hanmi Pharm. Co., Ltd. Composition for treating diabetes mellitus comprising insulin and a GLP-1/glucagon dual agonist
WO2015185640A1 (en) 2014-06-04 2015-12-10 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
EP4219565A1 (en) 2014-06-05 2023-08-02 Hanmi Pharm. Co., Ltd. Method for decreasing immunogenicity of protein and peptide
WO2015186988A1 (en) 2014-06-05 2015-12-10 Hanmi Pharm. Co., Ltd. Method for decreasing immunogenicity of protein and peptide
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10233230B2 (en) 2014-09-16 2019-03-19 Hanmi Pharm. Co., Ltd. Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
US10435459B2 (en) 2014-09-16 2019-10-08 Hanmi Pharm. Co., Ltd. Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
AU2015372767B2 (en) * 2014-12-30 2020-07-16 Hanmi Pharm. Co., Ltd. Glucagon derivatives
KR102418477B1 (en) * 2014-12-30 2022-07-08 한미약품 주식회사 Gluagon Derivatives
US11135271B2 (en) 2014-12-30 2021-10-05 Hanmi Pharm. Co., Ltd. Glucagon derivatives with improved stability
US12018060B2 (en) 2014-12-30 2024-06-25 Hanmi Pharm Co., Ltd. Glucagon derivatives
EA036479B1 (en) * 2014-12-30 2020-11-16 Ханми Фарм. Ко., Лтд. Peptide activating a glp-1 receptor and a glucagon receptor, pharmaceutical composition based thereon and use thereof in prevention or treatment of obesity
US11254724B2 (en) 2014-12-30 2022-02-22 Hanmi Pharm. Co., Ltd. Glucagon derivatives
EP3241841A4 (en) * 2014-12-30 2018-10-17 Hanmi Pharm. Co., Ltd. Glucagon derivative having improved stability
WO2016108617A1 (en) * 2014-12-30 2016-07-07 Hanmi Pharm. Co., Ltd. Glucagon derivatives
KR20160082026A (en) * 2014-12-30 2016-07-08 한미약품 주식회사 Gluagon Derivatives
EP3575314A3 (en) * 2014-12-30 2020-01-22 Hanmi Pharm. Co., Ltd. Glucagon derivatives
US10513550B2 (en) 2014-12-30 2019-12-24 Hanmi Pharm Co., Ltd Glucagon derivatives
US10806797B2 (en) 2015-06-05 2020-10-20 Sanofi Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate
US10696725B2 (en) 2015-06-30 2020-06-30 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
AU2016287209B2 (en) * 2015-06-30 2023-03-02 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
EP3322437A4 (en) * 2015-06-30 2019-10-09 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
KR102005456B1 (en) * 2015-06-30 2019-07-30 한미약품 주식회사 Novel glucagon derivative and a composition comprising a long acting conjugate of the same
US11667688B2 (en) 2015-06-30 2023-06-06 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
KR102395855B1 (en) 2015-06-30 2022-05-10 한미약품 주식회사 Novel glucagon derivative and a composition comprising a long acting conjugate of the same
WO2017003191A1 (en) 2015-06-30 2017-01-05 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
US11261227B2 (en) 2015-06-30 2022-03-01 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
IL256619A (en) * 2015-06-30 2018-04-30 Sung Youb Jung Glucagon derivative and a composition comprising a long acting conjugate of the same
CN108025041A (en) * 2015-06-30 2018-05-11 韩美药品株式会社 Hyperglycemic factor derivative and the composition for including its long-acting conjugate
KR20190092343A (en) * 2015-06-30 2019-08-07 한미약품 주식회사 Novel glucagon derivative and a composition comprising a long acting conjugate of the same
KR20170003466A (en) * 2015-06-30 2017-01-09 한미약품 주식회사 Novel glucagon derivative and a composition comprising a long acting conjugate of the same
US9982029B2 (en) 2015-07-10 2018-05-29 Sanofi Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
US10017557B2 (en) 2015-08-28 2018-07-10 Hanmi Pharm. Co., Ltd. Insulin analogs and use thereof
US10647753B2 (en) 2015-08-28 2020-05-12 Hanmi Pharm. Co., Ltd. Insulin analogs and use thereof
US11332508B2 (en) 2015-12-31 2022-05-17 Hanmi Pharm. Co., Ltd. Triple glucagon/GLP-1/GIP receptor agonist
US10370426B2 (en) 2015-12-31 2019-08-06 Hanmi Pharm. Co., Ltd Triple glucagon/GLP-1/GIP receptor agonist
US10981967B2 (en) 2015-12-31 2021-04-20 Hanmi Pharm. Co., Ltd. Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist
US10400020B2 (en) 2015-12-31 2019-09-03 Hanmi Pharm. Co., Ltd. Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist
KR102395856B1 (en) * 2016-06-29 2022-05-10 한미약품 주식회사 glucagon derivative, a conjugate thereof, and a composition comprising the same, and a therapeutic use thereof
CN109641035A (en) * 2016-06-29 2019-04-16 韩美药品株式会社 Glucagon derivative, includes its composition and its therapeutical uses at its conjugate
KR20180002544A (en) * 2016-06-29 2018-01-08 한미약품 주식회사 glucagon derivative, a conjugate thereof, and a composition comprising the same, and a therapeutic use thereof
WO2018004283A3 (en) * 2016-06-29 2018-02-22 한미약품 주식회사 Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
EP3479841A4 (en) * 2016-06-29 2020-03-04 Hanmi Pharm. Co., Ltd. Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
KR20190092344A (en) * 2016-06-29 2019-08-07 한미약품 주식회사 glucagon derivative, a conjugate thereof, and a composition comprising the same, and a therapeutic use thereof
KR102005457B1 (en) * 2016-06-29 2019-07-30 한미약품 주식회사 glucagon derivative, a conjugate thereof, and a composition comprising the same, and a therapeutic use thereof
US11142559B2 (en) 2016-06-29 2021-10-12 Hanmi Pharm. Co., Ltd. Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof
AU2017289014B2 (en) * 2016-06-29 2019-12-05 Hanmi Pharm. Co., Ltd. Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
IL263934B1 (en) * 2016-06-29 2023-06-01 Hanmi Pharm Ind Co Ltd Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
US11396534B2 (en) 2016-09-23 2022-07-26 Hanmi Pharm. Co., Ltd. Insulin analogs with reduced affinity to insulin receptor and use thereof
WO2018143729A1 (en) 2017-02-03 2018-08-09 한미약품 주식회사 Conjugate of bioactive material having enhanced sustainability and use thereof
US11752216B2 (en) 2017-03-23 2023-09-12 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof
WO2020017916A1 (en) 2018-07-19 2020-01-23 D&D Pharmatech Inc. Pharmaceutical composition comprising polypeptide
KR101990075B1 (en) * 2018-07-19 2019-06-18 ㈜ 디앤디파마텍 Pharmaceutical composition for preventing or treating obesity comprising a polypeptide
EP4148064A4 (en) * 2020-05-09 2024-06-12 Tianjin Institute Of Pharmaceutical Research Co., Ltd. Polypeptide derivative having dual receptor agonistic action and use thereof

Also Published As

Publication number Publication date
US9527898B2 (en) 2016-12-27
JP2019189611A (en) 2019-10-31
EP2718318A4 (en) 2014-12-31
AU2020201322B2 (en) 2021-04-29
JP7094327B2 (en) 2022-07-01
AU2018213964B2 (en) 2020-03-19
IL268984A (en) 2019-10-31
LT2718318T (en) 2018-10-25
CN103732618A (en) 2014-04-16
CN103732618B (en) 2018-10-09
CA2838503A1 (en) 2012-12-13
UA126465C2 (en) 2022-10-12
NZ748012A (en) 2020-01-31
SG10201604564XA (en) 2016-07-28
EP3434687A3 (en) 2019-02-20
RU2739209C2 (en) 2020-12-21
US20170022261A1 (en) 2017-01-26
ES2692187T3 (en) 2018-11-30
DK3878859T3 (en) 2024-01-02
WO2012169798A3 (en) 2013-02-14
US10442848B2 (en) 2019-10-15
UA114710C2 (en) 2017-07-25
TW201803895A (en) 2018-02-01
NZ717174A (en) 2017-07-28
CA2838503C (en) 2020-02-18
NZ731342A (en) 2017-09-29
US20140128318A1 (en) 2014-05-08
DK3434687T3 (en) 2021-06-07
CA3064214C (en) 2023-03-07
AU2012267398A1 (en) 2014-01-16
RU2612906C2 (en) 2017-03-13
NZ734808A (en) 2018-11-30
PL2718318T3 (en) 2019-02-28
EP3434687B1 (en) 2021-03-10
SI2718318T1 (en) 2018-11-30
AU2020201322A1 (en) 2020-03-12
RU2017105866A (en) 2019-01-23
US20150291679A1 (en) 2015-10-15
ES2875748T3 (en) 2021-11-11
CA3064214A1 (en) 2012-12-13
KR101573636B1 (en) 2015-12-03
AU2012267398B2 (en) 2016-10-13
HRP20181591T1 (en) 2018-11-30
IL245557B (en) 2018-12-31
KR20140130659A (en) 2014-11-11
KR101502299B1 (en) 2015-03-11
EP2718318B1 (en) 2018-07-25
HUE040307T2 (en) 2019-02-28
RU2017105866A3 (en) 2020-06-26
CY1120781T1 (en) 2019-12-11
AU2016273908B2 (en) 2018-08-23
EP3434687A2 (en) 2019-01-30
PT2718318T (en) 2018-11-09
ES2968043T3 (en) 2024-05-06
RU2013154066A (en) 2015-07-20
AU2016273908A1 (en) 2017-01-12
KR20120137271A (en) 2012-12-20
IL245557A0 (en) 2016-06-30
JP6014127B2 (en) 2016-10-25
US9522946B2 (en) 2016-12-20
JP2018117629A (en) 2018-08-02
JP2020183433A (en) 2020-11-12
US20170342122A1 (en) 2017-11-30
EP2718318A2 (en) 2014-04-16
JP2014516566A (en) 2014-07-17
IL268984B (en) 2021-04-29
MY169309A (en) 2019-03-21
AU2018213964A1 (en) 2018-08-23
JP6862493B2 (en) 2021-04-21
IL260582B (en) 2019-09-26
PE20240686A1 (en) 2024-04-10
PE20181299A1 (en) 2018-08-09
MX2022004041A (en) 2022-08-10
EP3878859A1 (en) 2021-09-15
NZ618810A (en) 2016-03-31
PE20140765A1 (en) 2014-06-14
MX2013014468A (en) 2014-05-13
NZ740049A (en) 2019-05-31
MX350708B (en) 2017-09-14
NZ755534A (en) 2020-10-30
ZA201309054B (en) 2014-08-27
BR112013031794A2 (en) 2016-12-20
TWI619724B (en) 2018-04-01
SG195258A1 (en) 2013-12-30
TW201307380A (en) 2013-02-16
JP6312765B2 (en) 2018-04-18
DK2718318T3 (en) 2018-11-05
AR086866A1 (en) 2014-01-29
TWI674271B (en) 2019-10-11
JP2017043624A (en) 2017-03-02
US9765131B2 (en) 2017-09-19
EP3878859B1 (en) 2023-11-01
RS57711B1 (en) 2018-12-31
CL2013003547A1 (en) 2014-06-27
BR122020011001B1 (en) 2022-09-20
BR112013031794B1 (en) 2020-11-10
DK3878859T5 (en) 2024-06-10

Similar Documents

Publication Publication Date Title
WO2012169798A2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
WO2016108586A1 (en) Glucagon derivative having improved stability
WO2012173422A1 (en) A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
WO2016108654A1 (en) Glp and immunoglobulin hybrid fc fused polypeptide and use thereof
AU2015372767B2 (en) Glucagon derivatives
WO2022245179A1 (en) Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist
WO2020017916A1 (en) Pharmaceutical composition comprising polypeptide
WO2021182928A1 (en) Novel bispecific protein and use thereof
NZ618810B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
NZ755534B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
NZ731342B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
NZ748012B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12797363

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2838503

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14124969

Country of ref document: US

Ref document number: MX/A/2013/014468

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2014514799

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013003547

Country of ref document: CL

Ref document number: 002789-2013

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: A201314212

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 2013154066

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2012267398

Country of ref document: AU

Date of ref document: 20120607

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013031794

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 245557

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 112013031794

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20131210